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ABSTRACT 
Type 1 diabetes mellitus (TlDM) results from the autoimmune destruction of the 
insulin producing P cells in the pancreas. In TlDM, insulin deficiency induces abnormal 
metabolism of glucose, lipids and protein that may result in elevation of reactive 
aldehydes methylglyoxal and glyoxal. Hyperglycemia and high levels ofmethylglyoxal 
and glyoxal can modify cell protein, promoting the formation of advanced glycation end-
products (AGEs), which may contribute to the development of diabetic complications. In 
this research, novel high-performance liquid chromatograph coupled with tandem mass 
spectrometric detection (LC-MS/MS) methods to measure plasma methylglyoxal, glyoxal 
and some of AGEs were developed. Plasma methylglyoxal, glyoxal and one AGE (MG-
Hl) were measured in young humans with complication-free TlDM. The activity of the 
ubiquitous membrane enzyme, Na+1K.+-ATPase, was also assessed. Fifty-six patients with 
TlDM (DM group), 6 to 22 years, and 18 non-diabetics (ND group), 6 to 21 years, were 
enrolled in the study. Mean hemoglobin AI C (%) was higher in the DM group (8 .5 ± 1.3; 
mean± standard deviation) as compared to the control group (5.0 ± 0.3). The mean 
plasma methylglyoxal (nmol/L) and glyoxal level (nmoVL), respectively, were found 
higher in the DM group (842 ± 238, 1052 ± 515) versus the control group (439 ± 90, 328 
± 208). Plasma free AGE, MG-Hl (mg/L), was also found to be higher in the DM group 
(2.7 ± 1.1) versus the ND group (1.7 ± 0.9), and weakly correlated with methylglyoxal 
levels but not glycemia as determined by AlC. Erythrocyte membrane Na+1K.+-ATPase 
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activity (nmol NADH oxidized/ min/mg protein) was elevated in the DM group (4.47 ± 
0.98) compared to the ND group (2.16 ± 0.59). Al C correlated with plasma 
methylglyoxal and glyoxal, and both aldehydes correlated with each other. A high 
correlation of AlC with Na+/K+-ATPase activity, and a regression analysis which showed 
that Al C was a good predictor ofthis enzyme activity, suggests that glucose may play a 
role in promoting membrane alterations. Increased plasma methylglyoxal, glyoxal, 
plasma free MG-Hl and erythrocyte Na+1K+-ATPase activity may predict the occurrence 
of future diabetic complications which may be prevented by early aggressive insulin 
treatment. 
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CHAPTER! 
INTRODUCTION AND OVERVIEW 
Type 1 Diabetes Mellitus (T1DM) is a common chronic condition in children that 
is characterized by hyperglycemia. Over time this results in complications like 
hypertension, nephropathy, retinopathy, and neuropathy. Hemoglobin Al C (A1 C) is a 
marker of glycemia and correlates with the risk of complications (Valeri et al., 2004). 
Some patients with good glycemic control develop severe complications, while others 
whose glycemic control may be inadequate remain relatively free of complications for 
long periods oftime (Forbes et al., 2005; Snieder et al., 2001). To date there is no 
biochemical test that can reliably predict clinical outcome in an individual patient. 
Determining a sensitive predictor or etiological basis of diabetic complications would 
allow for appropriate early interventions with reduction in morbidity and mortality in 
individuals with diabetes mellitus (DM) (Forbes et al., 2005). 
Advanced glycation end-products (AGEs) form as a result of a series of chemical 
reactions following glycation. In DM, hyperglycemia and altered glucose metabolism 
lead, to an excess generation of reactive aldehydes, like methylglyoxal and glyoxal 
(Ahmed and Thronalley, 2007). Both of these dicarbonyls are known to cause AGE 
formation by non-enzymatic reaction with the amino side chains of arginine or lysine, or 
the sulfhydryl groups of cysteines in proteins. AGEs and their precursors are found in 
many tissues including plasma. AGE formation may affect the structure and function of 
cellular proteins and membrane pump enzymes like Na+/K+-ATPase that control cellular 
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ions, and contribute to the pathogenesis of diabetic complications. In this study we 
developed methods to measure methylglyoxal and the structurally related dicarbonyl, 
glyoxal, and free AGE residues in plasma. The relationships between Al C, plasma 
methylglyoxal and glyoxal levels, and free AGE residues was assessed in young 
individuals with uncomplicated TlDM. We also explored the relationship between these 
factors and Na+1K.+-ATPase activity in the red blood cell (RBC) membrane. 
1.1 Type 1 Diabetes Mellitus (TlDM) 
1.1.1 Diabetes Mellitus (DM) 
DM is characterized by persistent and variable hyperglycemia (high blood glucose 
levels). The cost ofDM to healthcare and society in general is tremendous, and estimated 
at US$5.2 billion in Canada alone (Dawson et al., 2002). This includes an estimated $573 
million directly spent on DM care and another $63 7 million spent on diabetes related 
cardiovascular disease. 
DM is subdivided into 3 types depending on etiology. TlDM is caused by an 
absolute deficiency in insulin due to autoimmune destruction of islet 13 cells in the 
pancreas. Type 2 DM (T2DM) is associated with obesity and is characterized by tissue 
insulin resistance and inadequate insulin secretion. This may eventually progress through 
a number of phases finally resulting in B cell burnout and absolute insulin deficiency. A 
third type is gestational DM, a condition related to T2DM but presents as hyperglycemia 
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only during pregnancy (Canadian Diabetes Association Clinical Practice Guidelines, 
2003). 
TlDM, also known as insulin-dependent DM, childhood DM, or juvenile-onset 
DM, most commonly presents in children and adolescents. The typical age of onset is less 
than 25 years (Pepper, 2006). Also, in contrast to T2DM, TlDM occurrence is typically 
in individuals who are lean rather than obese (Ganong, 2003; Myers, 2005). The work of 
this thesis focuses on TlDM. TlDM constitutes approximately 10% of all individuals 
with DM and occurs mainly in populations of Europe and North America (Champe et al., 
2005; Gillespie, 2006; Habermann, 2006). TlDM is increasing in incidence globally at a 
rate of about 3% per year (EURODIAB ACE Study Group, 2000). There are isolated 
populations (such as in Newfoundland and Labrador) where TlDM is higher (Newhook, 
2004). In Newfoundland the incident rate ofTlDM is approximately 36 per 100,000 
compared with about 25 per 100,000 or less elsewhere in Canada. Like all types ofDM, 
TlDM is associated with increased risk for and a high incidence of certain complications. 
Hence, DM in general has been considered a syndrome of metabolic abnormalities (i.e. 
metabolic disorder of glucose, protein, lipids, water and electrolytes), microvascular 
disease (i.e. retinopathy, neuropathy, and nephropathy), and macrovascular disease (i.e. 
atherosclerosis) (Myers, 2005; Champe, et al., 2005). DM is the leading cause of adult 
blindness and amputation, and is a major cause of renal failure, heart disease, and stroke 
(Champe et al., 2005). Cardiovascular disease (CVD) is the main cause of premature 
death among people with DM - about 65% of people with DM die from heart disease or 
stroke (Geiss, 1995). TlDM patients are often young at the time of diagnosis. Although 
3 
the pathogenic factors are active early on, complications usually develop later as the 
disease progresses and are not as common during early stages. 
1.1.2 Potential Causes and Clinical Presentation of TlDM 
The precise triggers of the autoimmune destruction of islet B cells resulting in 
T1DM remain elusive (Wasserfall and Atkinson, 2006). However, some have suggested a 
role for CD4+ and CD8+ T lymphocytes and infiltrating macrophages in the destructive 
process (Foulis et al., 1991; Roep, 2003). B lymphocytes are also involved by producing 
autoantibodies (Brusko et al., 2005). 
The key determinants for the development ofT1DM seem to involve a genetic 
predisposition modified by environmental factors (Knip, 2003). The following 
susceptibility genes have been suggested to be involved in T1DM (Gillespie, 2006): the 
human leukocyte antigen (HLA) on chromosome 6 especially DR4-DQ8 and DR3-DQ2 
(Cudworth and Woodrow, 1975; Risch, 1987; Todd, 1995); the shorter number oftandem 
repeats, in a variable number of tandem repeats region, in the insulin gene promoter on 
chromosome 11 (Bennett et al., 1995); an allele of the gene for a negative regulator ofT-
lymphocyte activation, cytotoxic T lymphocyte antigen 4 (CTLA-4) found on 
chromosmone 2q33 (Gillespie, 2006); and a variant ofPTPN22, the gene encoding 
lymphoid tyrosine phosphatase (Bottini, et al., 2004; Gillespie, 2006). All four may be 
involved in the antigen presenting process involving T -lymphocytes. Environmental 
factors also appear to play a role in T1DM and may be responsible for the increasing 
incidence, although it is difficult to identify specifically which ones are most important. 
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Studies have also identified enteroviruses (Hyoty, 2002), rotavirus (Honeyman, 2000) 
and rubella (Ginsberg-Fellner et al., 1985) as possible pathogens involved in T1DM. 
Other factors include immunoregulatory defects, and formation of anti-islet antibodies 
against glutamic acid decarboxylase (Baekkeskov et al., 1989), a protein tyrosine 
phosphatase-like molecule (IA-2) (Lan et al., 1996) and insulin (Brusko et al., 2005). 
The clinical presentation ofT1DM is insidious, appearing rapidly at a stage when 
islet B cell levels have fallen to a critically low level. The most common symptoms and 
presenting features ofDM include polydipsia; drowsiness and fatigue; polyuria and 
bedwetting in children; polyphagia; vision changes (increased myopia); weight loss; 
sweet, fruity-smelling breath (due to ketone body production) and mood changes (Pepper 
2006). These symptoms are the result of inadequate blood insulin, hyperglycemia, and 
dehydration. 
1.1.3 Diagnosis of DM and Monitoring of Glycemia 
DM is a disease ofhyperglycemia and diagnosis ofboth T1DM and T2DM rely 
on demonstrating either a fasting or postmeal hyperglycemia (Canadian Diabetes 
Association Clinical Practice Guidelines, 2003). Normal blood glucose is typically less 
than 6.0 mmol/L in a fasting state. A fasting plasma glucose level~ 7.0 mmol/L (126 
mg/dL); a random plasma glucose~ 11.1 mmol/L (200 mg/dL); or a glucose value ~11.1 
mmol/L (200 mg/dL) two hours after a 75g oral glucose load on more than one occasion 
are diagnostic criteria for DM. These diagnostic criteria are defined based on risk for 
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diabetic retinopathy (Englegau, 1997). Individuals with levels of glycemia that are 
intermediate between normal levels and levels that are consistent with DM are 
categorized as being in a prediabetic state and are at risk of developing DM later on 
(Canadian Diabetes Association Clinical Practice Guidelines, 2003). 
Following the diagnosis of diabetes, long-term glycemic control is monitored 
using glycated hemoglobin (A1C). Normal adult hemoglobin A consists oftwo pairs of 
polypeptide chains, two a chains and two ~ chains. Long-term elevation of plasma 
glucose levels lead to small amounts ofhemoglobin A being non-enzymatically glycated 
to form A1 C. This occurs by glucose attaching to theN-terminal valine in each I3 chain of 
hemoglobin (Valeri et al., 2004) and occurs through Shiffbase formation followed by 
Amadori rearrangement to form the final stable glycation product (Figure 1.1 ). As the 
average life-span of a RBC is about 3 months, A 1 C levels serve as an estimate of the 
average glycemia over the previous 90 days. An elevated level of A1 C greater than 6.0% 
is considered abnormal and is common in individuals with DM. As a therapeutic goal, 
however, levels of A1C <7.0% are considered to be consistent with "good glycemic 
control" and lower risk for microvascular and macrovascular complications (Botero and 
Wolfsdorf, 2005; Canadian Diabetes Association Clinical Practice Guidelines, 2003). 
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N-terminal 
amino group 
f3A-NH2 + H-C=O 
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Figure 1.1 Formation of hemoglobin AlC. Hb A is hemoglobin A. f3A-NH2 refers to 
theN-terminal amino acid (valine) ofthe hemoglobin f3-chains. 
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1.1.4 Treatment of TlDM 
The control ofTlDM involves both lifestyle adjustments and medical treatments. 
Insulin replacement is the cornerstone of therapy for TlDM (Talreja, 2005; Canadian 
Diabetes Association Clinical Practice Guidelines, 2003). The optimal treatment 
regimens involve nutritious diet and exercise, which allow the patient to maintain a 
healthy, active lifestyle. Maintaining glycemic control is accomplished by therapeutic use 
of insulin and can prevent or minimize long-term microvascular complications ofDM 
(Habermann, 2006). Insulin must be administrated by subcutaneous injection 
(McCulloch, 2007). Many different insulin treatment regimes are used to control blood 
glucose levels. These vary in the speed and duration of a therapeutic effect and are 
variously referred to as rapid acting, short-acting, intermediate acting and long acting 
(Talreja, 2005; McCulloch, 2007). The best option depends upon a variety of individual 
factors (Habermann, 2006) and must be tempered with caution to avoid hypoglycemia. 
Conventional (standard) insulin treatment and intensive insulin treatment are the 
two main types of insulin treatment plans. These differ in the types and dose of insulin 
used and the frequency of injections. In general, intensive insulin therapy involves more 
frequent insulin injections or use of an insulin pump. Intensive insulin treatment also 
requires more frequent monitoring ofblood glucose. This type of therapy aims to more 
closely mimic insulin secretion by the pancreas and usually offers greater control of 
glycemia, (Habermann, 2006; Yki-Jarvinen, 1992), lower AlC, and therefore lower risk 
for complications (Habermann, 2006; Canadian Diabetes Association Clinical Practice 
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Guidelines, 2003). Conventional insulin treatment is an older regimen only 
recommended for selected patients (McCulloch, 2007). 
1.1.5 Complications of TlDM 
Poorly controlled T1DM carries an increased risk of developing both acute and 
chronic complications. Acute complications include diabetic ketoacidosis, hyperglycemic 
hyperosmolar coma, and hypoglycemic coma which can be life-threatening and, 
therefore, requires prompt treatment. The chronic complications are largely the effects of 
tissue damage occurring as a result of long term hyperglycemia and manifests as 
microvascular and macrovascular disease. Risk for the various complications are 
monitored by a variety of laboratory tests including A1 C, serum lipid levels, and urine 
albumin measurements, as well as clinical tests for peripheral neuropathy, blood pressure 
measurements, and ophthalmologic tests (Botero and Wolfsdorf, 2005; Canadian 
Diabetes Association Clinical Practice Guidelines, 2003). 
Both T1DM and T2DM are associated with increased risk of atherosclerosis and 
are associated with macrovascular disease like coronary artery disease (Wilson et al., 
1998; McGill et al., 1998; Giannattasio et al., 1999; Garber et al., 2003), stroke, and 
peripheral vascular disease. Coronary artery disease is twice as common in patients with 
DM as compared with non-diabetic patients and imparts greater risk of angina and 
myocardial infarction (Garber et al., 2003). Microvascular disease, including retinopathy, 
nephropathy and peripheral neuropathy, also occurs in both TlDM and T2DM owing to 
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overlap in their pathophysiology (Weiman, 2005). Diabetic retinopathy, a complication 
affecting the retina (Habermann, 2006; Myers, 2005, Talreja, et al., 2005), is the most 
common cause of blindness among non-elderly adults in western countries. Diabetic 
nephropathy involves damage to the kidney caused by the deterioration of renal blood 
vessels, which can lead to chronic renal failure, eventually requiring dialysis. DM is the 
most common cause of chronic kidney failure worldwide. Diabetic neuropathy involves 
abnormal and decreased sensation, usually starting in the feet but eventually spreading 
elsewhere. When combined with vascular disease, this can lead to diabetic foot, which 
may cause necrosis, infection and gangrene. Diabetic foot is also the most common cause 
of amputation in western countries, usually involving toes and feet (Weiman et al., 2005; 
Myers, 2005; Talreja, et al., 2005). Other forms of diabetic neuropathy may present as 
mononeuritis or autonomic neuropathy (Talreja, et al., 2005). 
1.1.6 Mechanisms of Complications 
Several mechanisms have been proposed to explain how elevated glucose levels 
may cause microvascular complications. The four main mechanisms involve 1) increased 
glucose flux through the polyol pathway (Engerman et al., 1994; Srivastava et al., 2005); 
2) increased glucose-induced activation of protein kinase C (PKC) isoforms (Koya and 
King, 1998); 3) increased production of reactive oxygen species (ROS) (Giugliano et al., 
1996); and 4) increased formation of AGE residues (Vlassara and Palace, 2002; Goldin et 
al., 2006). 
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Increased flux through the polyol pathway can cause damage in two ways. High 
glucose concentrations favor the conversion of glucose to sorbitol by aldose reductase 
activation. This also results in consumption ofNADPH and a decrease in the 
NADPH/NADP+ ratio (Srivastava et al., 2005). Oxidative stress caused by depletion of 
NADPH, and the osmotic stress induced by accumulation of sorbitol, both can result in 
tissue dysfunction and damage, leading to various complications (Srivastava et al., 2005). 
PKC consist oftwelve isoforms with different structure and co-factor 
requirements and is involved in signal transduction pathways affecting many 
physiological processes related to vascular function (Godbout et al., 2002). One of the 
key signaling events occurring during hyperglycemia is activation ofPKC (Koya and 
King, 1998) through increased release of diacylglycerol (DAG) as an intracellular second 
messenger. The mechanism of increased DAG synthesis involves elevated triose 
phosphates, dihydroxyacetone phosphate (DHAP) and glyceraldehydes-3-phosphate 
(G3P) concentrations during hyperglycemia. (Idris and Donnelly, 2006; Itani et al, 2002; 
Rolo and Palmeira, 2006). The damage resulting from PKC stimulation to the vascular 
tissue includes increased permeability, endothelial cell activation, altered blood flow, 
leukocyte adhesion and abnormal growth factor signaling, all of which contribute to 
several pathologies of diabetic complications (Brownlee, 2001). 
Potential role ofROS in the development ofDM complications has also been 
investigated (Baynes and Thorpe, 1999; Oberley 1988; and Ceriello et al. 2000). ROS, 
like superoxide and hydrogen peroxide, are constantly being generated as a consequence 
of aerobic metabolism. Nitric oxide, one of the reactive nitrogen species, is closely linked 
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to the ROS family and is generated by endothelial cells in response to stimuli like 
acetylcholine and insulin (Moncada et al. 1991). It plays an important role in regulation 
of vasomotor tone by stimulating cGMP formation and vasorelaxation. Nitric oxide can 
also rapidly react with superoxide to generate peroxynitrite, an extremely reactive oxidant 
(Cai and Harrison 2000), that can freely cross cell membranes (Curtin et al. 2002). 
Various metabolic changes occur during DM. Substrate flux through the mitochondria 
produce increasing levels ofROS (Baynes, 1991). This in tum can damage unsaturated 
fatty acids and proteins. The reaction ofROS with nitric oxide, to produce peroxynitrite 
can deplete nitric oxide, and cause the endothelial nitric oxide synthase (eNOS) to 
produce superoxide ion (Milstien and Katusic, 1999). Production of superoxide ion is 
important to generation of other ROS species that if not balanced by antioxidant defenses 
results in oxidative stress. Excessive ROS formation and increased vasoconstriction 
reduce blood flow and oxygen delivery. ROS decreases the expression of glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) resulting in increased levels of glyceraldehyde-3-
phosphate (G3P), increasing DAG generation and PKC activation, as well as increasing 
production of AGEs (Reusch, 2003). 
Finally, long term elevations of glucose and its metabolites promote formation of 
AGE residues which damage tissue proteins (Brownlee, 2001). This ultimately leads to 
damaged capillary basement membranes, vascular endothelium and other tissues, and the 
proliferation of vascular smooth muscle cells (VSMC) and platelet dysfunction- all 
contributing to the progression ofDM complications. (Goldin et al., 2006; Vlassara and 
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Palace, 2002). This final mechanism is of special relevance to this thesis and will be 
discussed in greater detail later. 
1.2 Methylglyoxal, Glyoxal and AGEs 
1.2.1 Metabolism of Methylglyoxal and Glyoxal 
The in vivo production ofmethylglyoxal and glyoxal can occur in all cell types, 
including VSMCs, and in blood plasma (Wu, 2006). Methylglyoxal (CH3-CO-CH=O or 
C3H402) (Figure 1.2) is a dicarbonyl formed as a byproduct of normal metabolism but 
has no known physiological function. It is also a highly reactive a-ketoaldehyde and can 
be produced from several sources by both enzymatic and non-enzymatic processes 
involved in glucose, lipid and protein metabolism. The major source of methylglyoxal 
involves the spontaneous transformation of triose phosphates from intermediates of 
glycolysis, including dihydroxyacetone phosphate (DHAP) and G3P (Thomalley, 1993b; 
Beisswenger et al., 2003) making it an intrinsic component of glucose metabolism via the 
glycolytic pathway (Figure 1.3). Under normal physiological conditions, glucose is 
converted to pyruvate via the glycolytic pathway forming only small amounts of 
methylglyoxal. GAPDH is a key enzyme in this process and is upregulated by insulin 
(Alexander et al., 1988). This enzyme is also believed to be modulated by a variety of 
other environmental and genetic factors, including TlDM (Beisswenger et al., 2003). 
Triose phosphates formed via the pentose phosphate pathway may also be a source of 
methylglyoxal (O'Brien et al., 2005). Factors that increase the availability of 
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methylglyoxal precursors such as increased plasma glucose (Thomalley 1988) or 
increases in fructose (Wang et al., 2006; Vasdev et al., 2003), glycine and threonine, and 
fatty acids may increase the formation of methylglyoxal. 
Glyoxal (OCHCHO or C2H202) is the smallest dialdehyde and is structurally 
related to methylglyoxal (Figure 1.2). Glyoxal's in vivo biosynthesis is also a byproduct 
of metabolism, but occurs mainly by oxidative degradation of glucose (Wells-Knecht, et 
al., 1995), lipid peroxidation (Shangari et al., 2003), oxidative degradation of DNA 
(Shangari et al., 2003), and oxidative degradation of fructosamine, a glucose-derived 
glycation product in proteins (Glomb and Monnier, 1995). Increased ROS, 
hyperglycemia, and glycated proteins containing fructosamine contribute to glyoxal 
formation in conditions like DM. 
The balance between synthesis and catabolism ofmethylglyoxal and glyoxal are 
important in maintaining their intracellular concentration. Both methylglyoxal and 
glyoxal are degraded intracellularly by reaction with glutathione, via the glyoxalase 
pathway (Abordo et al., 1999) (Figure 1.4). The altered activity of glyoxalase I and 
glyoxalase II may affect the degradation of both methylglyoxal and glyoxal (Abordo et 
al., 1999). Furthermore, factors affecting the availability of reduced glutathione like 
oxidative stress or activities of glutathione peroxidase and glutathione reductase, or 
glutathione synthase can also have profound effects on methylglyoxal and glyoxal 
catabolism through the glyoxylase pathway (Ahmed et al., 2002). 
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Figure 1.2 Structures of methylglyoxal, glyoxal, and some methylglyoxal and 
glyoxal derived advanced glycation end products (AGEs). Methylglyoxal-derived 
lysine dimer (MOLD), carboxyethyllysine (CEL), argpyrimidine, methylglyoxal-derived 
hydroimidazolones (MG-H) and Carboxyethyl-cysteine (CEC) are all products of 
methylglyoxal-induced glycation. Carboxymethyl-cysteine (CMC) is believed to be a 
product of glyoxal-induced glycation. 
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1.2.2 Formation of Methylglyoxal and Glyoxal in TlDM 
The production ofmethylglyoxal correlates with post-prandial glycemia in TlDM 
(Beisswenger et al., 2001). Plasma levels ofmethylglyoxal are higher in a group of 
combined adult T1DM and T2DM patients (Nemet et al., 2005). A number of processes 
may contribute to elevated methylglyoxal and glyoxal in T1DM. Insulin deficiency or 
inadequate insulin response, as well as altered glucose metabolism where the key enzyme 
of glycolytic pathway, GAPDH is down-regulated, can cause G3P to accumulate. This 
may lead to excess formation of methylglyoxal which also inhibits GAPDH and 
upregulates aldose reductase shunting glucose into the polyol pathway, resulting in 
accumulation ofG3P (Kashiwagi et al., 1992). Accumulation ofG3P, by both ofthese 
mechanisms, will result in excess formation ofmethylglyoxal in DM (Vander Jagt et al., 
1993; Phillips et al., 1993). 
In T1DM, insulin deficiency enhances lipolysis and may increase the generation 
of methylglyoxal during metabolism of acetone catalyzed by semicarbazide-sensitive 
amine oxidase (SSAO) or acetol mono-oxygenase (Casazza et al., 1984; Lyles and 
Chalmers, 1992). SSAO is found in high amounts within VSMCs and in plasma (Ekblom 
1998), possibly originating from VSMC secretion. Low insulin levels in T1DM also 
induce excess protein catabolism. Methylglyoxal may also form from amino acetone, an 
intermediate formed during catabolism of glycine and threonine (Ray & Ray, 1987; Lyles 
and Chalmers 1992). 
The concentrations of blood methylglyoxal and the activity of glyoxalase I and II 
are increased in T1DM and T2DM adults with complications (McLellan 1994). It has 
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been observed that in TlDM patients without retinopathy there is higher activity of 
glyoxalase II than those with retinopathy (Thomalley et al., 1989). This suggests a 
protective role for high glyoxylase II activity and a possible causal role for methylglyoxal 
in retinopathy. Oxidative stress also decreases the levels of glutathione required for the 
catabolism of methylglyoxal and glyoxal in the glyoxylase pathway. Thus, an imbalance 
between the formation ofmethylglyoxal and glyoxal, and its catabolism in T1DM results 
in their accumulation. It is, therefore, not surprising that methylglyoxal induced glycation 
is increased disproportionately in relation to the increase in glucose in DM (Ahmed and 
Thomalley, 2007). 
1.2.3 Formation and Degradation of AGEs 
Under normal physiological conditions, AGEs are formed by normal metabolism 
and aging as a result of oxidative and peroxidative stress. However, when glucose is 
elevated, or methylglyoxal or glyoxal are increased (due to increased production or 
decreased catabolism), AGEs may be formed in excess. The early glycation products 
formed by modification ofN-terminal amino groups or lysyl chains by glucose via the 
Maillard reaction are reversible and require further oxidation to produce stable products 
like that involved in A1C formation. Both methylglyoxal and glyoxal are highly 
electrophilic and react non-enzymatically with free amino (-NH2) or sulfhydryl ( -SH) 
groups of lysine, arginine or cysteine of intra- and extracellular proteins to form AGEs 
(O'Brien et al., 2005) (Figure 1.5). 
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The formation of AGEs is irreversible and stable (Wu, 2006; O'Brien et al., 
2005). Their aldehyde precursors are up to 20,000 times more reactive than glucose in 
glycation processes (Thornalley 2005) and methylglyoxal is the most reactive of the AGE 
precursors (Kilhovd et al., 2003). These modifications to protein structure can directly 
alter protein function (Goldin et al., 2006). AGE residues can also act indirectly through 
cell surface receptors such as the receptor of AGEs (RAGEs) and scavenger receptors to 
alter tissue function (Jensen et al., 2005; Horiuchi et al., 2003). 
AGE residues represent a chemically heterogenous group with over 30 different 
ones already described and possibly many more yet to be discovered. AGE residues can 
only be removed through proteolysis. The tum-over of AGE damaged proteins can be 
very slow depending on the protein and its location, but proteolysis results in the 
appearance of nonprotein-bound free AGE residues in biological fluids (Thornalley et al., 
2003). Those appearing in the blood plasma may eventually be excreted in the urine if 
there is adequate renal function (Thornalley et al., 2003). AGE residues are also formed 
exogenously by heating, or cooking, sugars with fats or proteins (Koschinsky, 1997). The 
absorption of AGE residues from these thermally processed foods in the gastrointestinal 
tract may contribute to plasma free AGE residue concentrations (Ahmed and Thornalley, 
2007). Free AGE residues re-absorbed from the kidney filtrate may also contribute to the 
plasma concentrations of free AGE residues (Ahmed and Thornalley, 2007). 
Methylglyoxal may bind free arginine in plasma but it is not known whether this 
contributes largely to free MGH-1 levels. 
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1.2.4 Methylglyoxal and Glyoxal Derived AGE Residues 
A number of AGEs form from methylglyoxal and glyoxal (O'Brien et al., 2005). 
Methylglyoxal can produce a number of stable AGEs, including Ns-carboxyethyl-lysine 
(CEL), the methylglyoxal-derived hydroimidazolones (MG-H), argpyrimidine, and 
methylglyoxal-derived lysine dimer (MOLD) (Figure 1.2). The latter is formed by cross-
linking two lysine residues of proteins which can also act to crosslink different proteins in 
vivo. CELis also formed by the reaction ofmethylglyoxal with lysine. MG-H and 
argpyrimidine are formed by the reaction of methylglyoxal with arginine. The 
modification of arginine residues in proteins can be of particular functional relevance 
considering the high frequency with which arginine residues appear at ligand binding 
sites and active sites of enzymes (Thomalley, 2005). MG-H is a collection of at least 
three different isomers, MG-Hl, MG-H2, and MG-H3 which differ from each other in 
stability (Ahmed et al., 2002). MG-Hl and MG-H2 appear to be most stable at 
physiological pH, whereas, MG-H3 is rapidly broken down (Ahmed et al., 2002). The 
MG-Hl isomer occurs as two epimers and is of great physiological relevance. 
AGE residues can also form as a result of reactions involving glyoxal (O'Brien et 
al, 2005). For example, reaction of glyoxal with lysine forms glyoxal-lysine dimer 
(GOLD) and carboxymethyl lysine (CML); and reaction with arginine forms the glyoxal-
derived hydroimidazolone (G-Hl ). Methylglyoxal and glyoxal are also known to react 
both reversibly and irreversibly with cysteine sulfhydryl (Zeng and Davies, 2005) 
forming carboxyethyl cysteine (CEC) and carboxymethyl cysteine (CMC), respectively, 
as the stable irreversible products (Zeng and Davies, 2005). All of these are present in 
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plasma and tissue proteins, but MG-Hl appears to dominate as the major methylglyoxal-
derived AGE (Ahmed et al, 2005). Free MG-Hl also seems to be the main free AGE 
residue present in plasma, where levels of the others may be undetectable in healthy 
individuals (Ahmed et al, 2005). MG-Hl is increased in adults with TlDM (Ahmed et al., 
2005). 
1.2.5 Effects of Methylgyloxal, Glyoxal and AGE Residues 
Methylglyoxal and glyoxal have been shown to cause detrimental effects to 
protein function. Whether this occurs via a non-AGE or AGE-related mechanism has not 
been confirmed. Numerous studies show that these aldehydes form AGEs changing the 
structure and function of proteins. The effects of AGEs may also be indirect, mediated 
through AGE receptors, like RAGEs or scavenger receptors. 
1.2.5.1 Effects of methylglyoxal on gene transcription 
Methylglyoxal-derived AGE residues can also be formed by reaction with the 
guanyl residues of RNA and DNA. Reaction ofmethylglyoxal with guanyl residues in 
DNA and RNA can lead to transcriptional abnormalities (Wu, 2006) including single 
strand breaks and teratogenic effects (Vlassara and Palace, 2002). Methylglyoxal may 
also directly regulate transcription of genes that are involved in acellular capillary 
formation causing endothelial cell death and vessel regression (Yao et al., 2006; 
Ramasamy et al., 2006). A mechanism has been proposed whereby methylglyoxal 
modification ofmSin3A decreases mSin3A binding to the angiopoietin-2 promoter, 
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leading to an increase in angiopoietin-2 expression (Yao et al., 2006). Angiopoietin-2 and 
other proangiogenic factors play a key role in proliferative changes that characterize the 
advanced stages of diabetic retinopathy. 
1.2.5.2 Effects of methylglyoxal on vascular calcium homeostasis 
Methylglyoxal may contribute to enhanced vascular contractility or impaired 
endothelial-dependent vascular relaxation by altering calcium homeostasis in VSMCs 
and endothelial cells. Chronic treatment ofWKY rats with oral methylglyoxal elevates 
intracellular calcium level in platelets (Vasdev et al. 1998b ). Vascular calcification is a 
common feature in advanced atherosclerosis. High intracellular calcium levels in VSMC 
can increase vascular contractility, inducing further cardiovascular disease including 
angina and myocardial infarction (Y amagishi et al., 2007). 
1.2.5.3 Effects of methylglyoxal on reactive oxygen species and oxidative stress 
Endothelial cell function may also be affected through an inhibitory effect of 
methylglyoxal on nitric oxide synthesis, decreasing the bioavailability of nitric oxide and 
thereby increasing monocyte adhesion, platelet aggregation and VSMC proliferation 
(Wu, 2006). Methylglyoxal affects vascular function through its ability to generate ROS. 
Methylglyoxal is known to induce oxidative stress by a mechanism involving decreased 
levels of reduced glutathione, and lower glutathione reductase and glutathione peroxidase 
activities (Wu and Juurlink, 2002). Methylglyoxal also significantly increases superoxide, 
hydrogen peroxide production (Wu, 2006) and peroxynitrite production in VSMC (Chang 
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et al. 2005), impairing nitric oxide function. Blood cells are affected as well. For example 
methylglyoxal induces superoxide and hydrogen peroxide formation in neutrophils, 
potentially leading to kidney damage (Ward and McLeish 2004), and in the presence of 
thrombin, methylglyoxal induces a platelet peroxide accumulation and aggregation 
(Leoncini and Poggi 1996). The combined effect of increased ROS and decreased nitric 
oxide generation may include VSMC apoptosis, altered vascular tone, endothelial 
dysfunction and hypertension. 
1.2.5.4 Effects of methylglyoxal on cell signaling and vascular proliferation 
Methylglyoxal increases the activation ofNF-KB p65, a transcription activator 
involved in inflammatory and proliferative vascular response, in cultured VSMC from 
aorta (Wu and Juurlink 2002) and mesenteric artery (Wu 2005). This may occur as a 
result ofmethylglyoxal-induced oxidative stress, as hydrogen peroxide also activates NF-
KB p65 in spontaneously hypertensive rat VSMC (Wu and Juurlink 2002), and 
superoxide, peroxynitrite, and hydrogen peroxide can activate NF-KB in human 
endothelial cells (Canty et al. 1999; Ogata et al. 2000;Cooke and Davidage 2002). Hence, 
methylglyoxal may also be an important promoter ofNF-KB activation, contributing to 
vascular proliferation during development of vascular disease. 
Methylglyoxal can also affect cell signaling through interaction with components 
of the mitogen-activated protein kinases (MAPK) system, which includes a number of 
serine and threonine protein kinases that can induce cell proliferation. Methylglyoxal 
induces the expression of heparin-binding epidermal growth factor in rat aortic VSMC 
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(Che et al. 1997) and inhibits cellular response to human insulin-like growth factor-1 
through a MEK/ERK -dependent pathway in cultured human embryonic kidney cell line 
and mouse fibroblast cell line (Du et al. 2003). Thus, methylglyoxal may cause abnormal 
cell growth. 
There is strong evidence that the accumulation of methylglyoxal modifies cellular 
protein function, gene transcription and other cell-response-related factors, thereby 
altering vascular function and mediating vascular disease. While these effects have been 
ascribed to methylglyoxal it is likely that at least some of these are mediated through 
AGE formation and/or activation of specific AGE receptors. These events may be 
involved in the pathogenesis of microvascular and macro vascular disease in DM. 
1.2.5.5 Effects of Glyoxal 
Both methylglyoxal and glyoxal have mutagenic properties (Takahashi et al., 
1989). Glyoxal has been shown to inhibit GAPDH and glutathione reductase in vitro 
(Morgan 2002). Also like methylgloxal, many of the effects of glyoxal appear to be 
mediated through formation of glyoxal AGEs. These effects may explain the increased 
susceptibility to hydrogen peroxide, increased ROS generation, reduced glutathine levels 
and decreased mitochondrial membrane potential caused by treatment with glyoxal 
(Shangari and O'Brien, 2004). Glyoxal showed site specific modification of ribonuclease 
by binding to arginine close to the enzyme active site (Cotham et al., 2004). The in vivo 
formation of GOLD has also been reported (Yamada et al, 2004; Lederer and Klaiber, 
1999). Levels of other glyoxal AGE residues like CML and CMC are increased in tissue 
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proteins in response to oxidative stress and DM (Zeng and Davies, 2005; Ahmed and 
Thomalley, 2007; Mostafa et al., 2007). Both G-H1 and CML in plasma protein 
correlates with levels of A1 C (Ahmed et al., 2005), and CML tends to accumulate in 
collagen with age (Baynes, 1991 ). The close relationship between fructosamine and 
glyoxal formation and hence the formation of glyoxal-derived AGE residues make 
glyoxal and glyoxal-derived AGE residues surrogate markers ofDM (Ahmed and 
Thronalley, 2007). This is in contrast to AGE residues derived from methylglyoxal where 
there seems to be greater dependancy on glucose metabolism than glycemia per se. 
1.2.5.6 Direct effects of AGE residues 
The formation ofmethylglyoxal-derived AGEs may be a major mechanism by 
which methylglyoxal induced cell damage and dysfunction occurs (Goldin et al., 2006). 
Methylglyoxal as well as glyoxal-derived AGEs are known to accumulate with ageing. 
Formation of AGEs can alter function of cellular enzymes, receptors, carriers and 
structural proteins. For example AGE residues are known to cross-link human vitreous 
collagen potentially contributing to progression of retinopathy (Frye et al., 1998, Stitt et 
al., 2002). AGE modification of large matrix proteins like collagen, laminin and 
vitronectin alter their molecular charge, the three dimentional matrix assembly, and 
binding properties which has significant effects on the polyanionic nature and properties 
of the basement membrane (Vlassara and Palace, 2002). Treatment ofhuman albumin 
with relatively low concentration of methylglyoxal is known to result in formation of 
MG-H residues that affect the drug binding function and esterase activity of albumin in 
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vitro (Ahmed et al., 2005 JBC). Heat shock protein 27 has been identified as a major 
methylglyoxal-modified protein in endothelial cells but argpyrimidine, rather than MG-
Hl, appears to be the main adduct in this case and may repress cytochrome c-mediated 
caspase activation (Sakamoto et al, 2002). Heat shock protein 27 is one of the chaperones 
that protects the cell against ischemic damage and inhibits cell death (Oya-Ito et al., 
2006). AGE modification of intracellular basic fibroblast growth factor dramatically 
reduces the mitogenic activation of endothelial cell cytosol (Giardino et al., 1994) which 
may alter endothelial cell growth and basement membrane production. 
1.2.5.7 Indirect effects of AGE residues 
Circulating AGEs may interact with putative cell surface receptors for AGEs 
(Ahmed and Thomalley, 2007). These include the scavenger receptors, a specific receptor 
referred to as RAGE, and galectin 3. A number of intracellular AGE binding proteins 
have also been described (Ahmed and Thomalley, 2007). The scavenger receptors and 
galectin-3 recognizes protein highly modified with AGE residues. The scavenger receptor 
appears to be involved with clearance and degradation of AGE modified proteins by 
macrophages and macrophage-derived cells and may play a role in the pathogenesis of 
atherosclerosis (Nagai et al., 2007). Galectin-3 is also found on macrophages (Vlassara et 
al, 1995) and is believed to have a proinflammatory effect during the development of 
diabetic nephropathy (Kikuchi et al., 2004). RAGE is a membrane protein with wide 
tissue distribution and substrate-binding specificity. RAGE is expressed on endothelial 
cells, VSMCs, immune system cells, in the lung, liver, kidney and blood cells. 
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Extracellular methylglyoxal-modified protein can be removed by RAGE, internalized and 
subsequently degraded by proteolysis (Ramasamy et al., 2006). 
Activation of RAGE by AGE binding is known to activate a multitude of cellular 
signaling pathways mediating a number of intracellular events which ultimately have 
implication for chronic disease. The activation of various signal transduction cascades are 
known to result in down-stream production ofNF-kB and several other transcription 
factors (Li and Schmidt, 1997). NF-kB dependent gene expression affects cytokine, 
procoagulant, prothrombotic, and vasoconstrictive gene products including increased 
NADPH oxidase and iNOS expression (Wu et al, 2002). NF-kB increases expression of 
cellular adhesion molecules like intracellular adhesion molecule-1 (ICAM-1) which has 
been linked to general vascular disease (Barnes and Karin, 1997). Effects of RAGE on 
the suppression of glutathione and ascorbic acid levels contribute to oxidative stress and 
ROS accumulation (Lander et al., 1997; Bierhaus et al., 1997). Furthermore, the depletion 
of glutathione decreases glyoxalase I activity which compromises the ability to further 
control intracellular AGE formation via methylglyoxal and glyoxal. The binding of AGEs 
to RAGE on the endothelium also results in expression of inflammatory factors such as 
VCAM-1 and Tumor necrosis factor a (TNF-a) (Goldin et al., 2006). 
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1.2.6 Methylglyoxal, Glyoxal, AGEs and Diabetic Complications 
Methylglyoxal, glyoxal and AGE formation are believed to play a causative role 
in the vascular complications ofTlDM and T2DM (Ahmed and Thomally, 2007; 
Vlassara and Palace, 2002; O'Brien and Shangari, 2004). There is evidence in adults with 
TlDM and TlDM animal models that plasma methylglyoxal is elevated and that 
methylglyoxal- and glyoxal-derived AGEs are involved in the pathological changes in 
various tissues (Degenhardt et al., 2002; Karachalias et al, 2003; Beisswenger et al., 
2003a, 2003b) resulting in microvascular and macrovascular complications ofDM 
(Figure 1.6). Karachalais et al. (2003) showed that levels ofCML, CEL, G-Hl and MG-
Hl are variably increased in proteins of renal glomeruli, retina, sciatic nerve and plasma 
of streptozotocin-induced TlDM rats, consistent with a significant role of methylglyoxal 
and glyoxal in the development of nephropathy, retinopathy, and neuropathy. Increased 
levels of protein bound AGEs in humans with DM complications suggests a relationship 
between protein-bound AGE levels and complications. In humans with DM, the levels of 
specific methylglyoxal-AGEs in plasma proteins are increased and correlates with indices 
of complications. For example, the levels of serum protein bound argpyrimidine is 
increased 2 to 3 times in middle aged and elderly adult DM patients and correlates with 
levels of glycated hemoglobin (Wilker et al, 2001). Concentrations of plasma protein 
bound CEL and CML are increased in adult TlDM patients with decreased glomerular 
filtration rate and correlates with blood concentrations of markers of endothelial 
dysfunction (Lieuw-A-Fa et al, 2004). Plasma protein bound MG-H concentrations are 
also increased in adult TlDM patients (Ahmed et al., 2005 D) and elder T2DM patients 
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Diabetes-induced hyperglycemia and altered glucose 
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Figure 1.6 Proposed role of methylglyoxal and methylglyoxal-derived AGEs in DM. 
The abbreviations are: AlC is hemoglobin AlC; MG is methylglyoxal; RAGE is receptor 
for advanced glycation end products; AGEs is advanced glycation end products; and DM 
is diabetes mellitus. 
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and correlates with CML levels (Kilhovd et al, 2003). The glycation cross-linked MOLD 
is increased in adult T1DM patients (Ahmed et al., 2005), but none of the methylglyoxal 
derived AGEs apparently correlated with A1 C levels in the adult DM patients (Ahmed et 
al., 2005; Kilhovd et al, 2003). The accumulation of AGE residues in tissues and in 
plasma protein is consistent with a role for AGEs in DM complications. 
In animal studies, the injection ofmethylglyoxal (Berlanga et al., 2005) or AGE-
modified protein can induce vascular damage similar to that observed in DM (Vlassara et 
al., 1992; Vlassara et al., 1995) including increased vascular permeability, expression of 
vascular adhesion molecules, and decreased nitric oxide generation. Furthermore the 
short-term administration of exogenous AGE in normal, non-diabetic animals was 
associated with increased production of collagen IV, a basement membrane component, 
and with other findings consistent with diabetic nephropathy (Yang et al., 1994; Vlassara 
et al., 1992). This suggests a causal role for methylglyoxal and methylglyoxal-AGEs in 
DM complications. In mice with streptozotocin-induced T1DM, treatment with 
aminoguanidine (an advanced glycation inhibitor) or ALT-711 (an AGE cross-link 
breaker) reduced both vascular AGE accumulation and atherosclerosis (Forbes et al., 
2004). The accumulation ofCEL and MG-H in renal glomeruli, retina, sciatic nerve, and 
plasma proteins (Babaei-Jadidi et al., 2003) precede the development of nephropathy in 
streptozotocin-induced T1DM in rats. Subsequent treatment of these animals with high 
doses of thiamine and benfotiamine therapy to increase metabolism of G3P through 
transketolase and the pentose phosphate shunt (and thereby prevent methylglyoxal 
formation) reduced the blood levels ofmethylglyoxal, MG-H and CEL, and prevented the 
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progression to retinopathy (Hammes et al, 2003). This was accomplished without any 
change in glycemia or A1C. Pyridoxamine inhibits the formation of AGE residues and 
also inhibits the development of retinopathy and neuropathy in streptozotocin-induced 
DM in rats (Degenhardt et al., 2002; Stitt et al., 2002). Taken together these studies are 
consistent with a causal role ofmethylglyoxal and methylglyoxal-derived AGE residue 
formation as independent and contributing factors in the development ofDM vascular 
complications. 
AGEs may also play a causal role in the pathological process leading to DM 
complications through effects mediated through RAGE. Increased RAGE expression in 
the endothelium of activated vessels is observed in DM humans (Ritthaler et al, 1995; 
Feng et al., 2005) and contributes to a chronic low grade inflammation (Stehouwer et al., 
2002) and is believed to accelerate atherosclerosis (Naka et al., 2004) and hypertension 
(Schram et al., 2005). Binding of AGE residues to AGE receptors on neonatal rat 
mesangial cells in vitro results in overproduction of matrix proteins and induction of 
mesangial oxidative stress and PKC activation (Scivittaro et al., 2000), both ofwhich are 
potential mechanisms of microvascular disease. Treatment of cultured human mesangial 
cells with an anti-AGE agent, N-acetylcysteine, inhibited vascular endothelium growth 
factor (VEGF) and MCP-1 secretion and apoptosis (Yamagishi et al., 2002). 
Overexpression of RAGE in DM mice increased albuminuria, serum creatinine, renal 
hypertrophy, mesangial expansion and glomerulosclerosis compared to non-diabetic 
littermates (Yamamoto et al., 2001). These changes were restored by blockade of RAGE 
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(Wendt et al., 2003). Furthermore, a diffuse upregulation of RAGE expression occurs in 
renal glomerular podocytes in patients with diabetic nephropathy (Tanji et al., 2000). 
These studies indicate a role of RAGE in diabetic nephropathy and possibly other 
complications (Ahmed et al, 2007). 
1.2.7 Previous Methods for Measurement ofMethylglyoxal, Glyoxal and AGEs 
A number of methods have been published for quantification ofmethylglyoxal 
and other dicarbonyls with it. One of the first methods published to measure 
methylglyoxal in blood relied on derivatization with 1 ,2-diamino-4,5-dimethoxybenzene, 
followed by solid phase extraction (SPE), and finally reversed phase-HPLC 
chromatography and detection of the quinoxaline product by spectrophotometric or 
fluorescent properties (McLellan et al., 1992). Several other HPLC based techniques 
based on fluorometric or spectrophotometric detection have also been described (Ohmori 
et al., 1987; Cordeiro et al, 1996; Thomalley et al., 1999; Nemet et al., 2004; Chaplen et 
al., 1996, Espinosa-Mansilla et al., 1998). Most ofthese make use of aromatic diamino 
compounds as derivatizing agents. Recently, methods have been published based on the 
quantification of dicarbonyl adducts including methylglyoxal and glyoxal with 2,3-
diaminonaphthalene (Odani et al., 1999) or a-phenylenediamine (Randell et al., 2005) 
using electrospray ionization liquid chromatography/mass spectrometry (ESIILC/MS), or 
quantifying pentafluorobenzyl hydroxylamine adducts using gas chromatography/mass 
spectrometry (GC/MS) (Lapolla et al., 2003). Single phase LC/MS and GC/MS methods 
34 
lack the specificity of a LC/MS/MS method, and the solid phase extraction step included 
in a number of these methods may be cost prohibitive. 
Relatively few methods have been published for measurement ofmethylglyoxal-
derived AGE residues as a group (Ahmed et al., 2002; Ahmed et al., 2005). Pure 
standards are not commercially available for any of the methylglyoxal-derived AGE 
residues. Hence, any work in this area requires synthesis of the various AGE residues as a 
first step. Most of the quantitative methods available rely on LC-MS/MS (Mostafa et al., 
2007; Teerlink et al., 2004 CC) or GC-MS (Petrovic et al., 2005) and measure only one 
or two different AGE residues. Only a few laboratories around the world have the 
capability to measure these. In general these methods are cumbersome. Thornalley et al 
(2003) recently published a method for measurement of a wide variety of free and bound 
AGE residues without derivatization. The method involves a rather complex column 
switching technique and the analysis time per sample was also relatively long (40 to 50 
min). 
1.3.1 Structure and Function ofNa+/IC-ATPase 
Na+1K+-ATPase (Sodium-potassium-activated adenosine triphosphatase) is 
present in the plasma membrane of all eukaryotic cells and helps maintain cell potential 
through maintainance of the electrochemical gradients ofNa+ and K+. Na+1K+-ATPase 
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activity also contributes to the control of cellular pH, osmotic balance and therefore cell 
volume, as well as to the Na+-coupled transport of nutrients such as amino acids and 
vitamins in all cells (Sherwood, 2001). In intestinal and renal tubular cells, it provides the 
energy for the uptake of glucose. 
Na+1K.+-ATPase catalyzes the hydrolysis of one mole of ATP to ADP. This energy 
is used to extrude three Na+ ions from the cell and causes the uptake of two extracellular 
K+ ions into the cell (Ganong, 2003; and Kaplan, 2002). Na+1K.+-ATPase is not a single 
protein enzyme but is part of a super family consisting of more than 300 members 
(Kaplan, 2002). Na+/K+- ATPase consists oftwo subunits, a-subunit and ~-subunit 
(Kaplan 2002; Jergensen, 2003; Ganong, 2003; Aperia, 2007) (Figure 1.7), each ofwhich 
are heterogeneous consisting of several isoforms with different tissue specificity 
(Ganong, 2003; Levenson, 1994; Sweeney and Klip, 1998; Kaplan, 2002). The ~-subunit 
ofNa+1K.+-ATPase is a glycoprotein and is involved in delivery and maintaining correct 
orientation ofthe a-subunit (Aperia, 2007, Ganong, 2003). The a-subunit ofNa+/K+-
ATPase has intracellular Na+ and ATP binding sites and a phosphorylation site. The 
extracellular portion of this subunit has a K+ and an ouabain-binding site (Ganong, 2003). 
Ouabain is an inhibitor of the enzyme. The mechanism of action is relatively 
straightforward. The a-subunit ofunphosphorylated Na+/K+-ATPase binds to Na+. This is 
followed by ATP binding and hydrolysis leading to phosphorylation of the pump 
(Ganong, 2003). Phosphorylation results in reduced affinity for Na+ which is released 
into the extracellular fluid. Subsequent binding of K+ results in dephosphorylated and 
transport ofK+ into the cytoplasm (Ganong, 2003). This process helps maintain the Na+ 
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and K+ electrochemical gradients across plasma membrane and physiological function of 
the cell. 
1.3.2 Regulation of Function ofNa+/~-ATPase 
Regulation ofNa+/K+ pump activity is mainly through the a subunit. An 
important short term regulation is the intracellular concentration ofNa+ (Sweeney and 
Klip, 1998; Kaplan, 2002; ganong, 2003). Elevated intracellular Na+ concentrations 
increase the activity ofNa+/K+ ATPase resulting in rapid removal of excess Na+ and 
restore low steady-state concentrations (Sweeney and Klip, 1998; Kaplan, 2002; Ganong, 
2003). Other short term regulation is through phosphorylation and dephosphorylation, 
translocation of subunits to the plasma membrane or by modification ofNa + affinity 
(Ewart and Klip, 1995). Long term regulation of a1 subunit occurs through effects on 
gene transcription, translation and degradation of the protein (Ewart and Klip, 1995). 
Na+1K+-ATPase is upregulated by several hormones including aldosterone, thyroid 
hormone, endothelin, acetylcholine and insulin in muscle, fat, and kidney cells and 
erythrocyte (Ewart and Klip,1995; Baldini et al., 1986). Insulin stimulates the Na+/K+-
ATPase by increasing intracellular Na+ concentration (Brodsky JL. 1990), stimulating 
translocation of the pump subunits, promoting phosphorylation, increasing sensitivity of 
Na+1K+-ATPase to Na+ (Feraille et al., 1994) and by increasing its biosynthesis (Sweeney 
and Klip, 1998). 
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3Na+ I \ ATP Phosphorylation 
Figure 1.7 Structure ofNa+/K+-ATPase in membrane. ATP is the abbreviation of 
adenosine triphosphate. 
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1.3.3 DM, Methylglyoxal and Erythrocyte Na+/K+-ATPase 
Abnormalities in Na+1K+-ATPase activity are thought to be involved in 
development ofheart disease, neuropathy, hypertension, and cataracts (Garner 1986 
EER; Jannot et al., 1999). RBC membrane Na+1K+-ATPase can be separated from 
cytoplasmic components and its activity measured. Na+/K+-ATPase levels are low in 
adult T 1 DM and are strongly related to diabetic neuropathy (J annat et al, 1999, Raccah et 
al1996). Methylglyoxal inhibited Na+/K+-ATPase activity in RBC ghost cell membrane 
of normal human subjects likely occurs via the modification of sulfhydryl groups 
(Derham et al, 2003). In young complication-free TIDM patients there was no change in 
RBC Na+1K+-ATPase activity (Deak 2003). Rats showed a biphasic response with an 
increase in activity of this enzyme in medullary thick ascending limb ofkidney 6 weeks 
after induction ofT1DM, followed by a decrease at 12 weeks (Tsimaratos 2001). A 
decrease in Na+1K+-ATPase activity compromises microvascular blood flow by affecting 
microvascular regulation and decreasing RBC flexibility leading to an increase in blood 
viscosity. The DM-induced impairment in Na+1K+-ATPase activity is identical in RBC as 
that in neural tissue. RBC ATPase activity is related to nerve conduction velocity in the 
peroneal and the tibial nerve in patients with DM. 
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1.4 Research Proposal and Objectives 
Elevations in methylglyoxal, glyoxal and AGEs may preceed and contribute to the 
pathogenesis of complications in DM. Other processes such as normal aging, impaired 
renal function, and other conditions can also contribute to the elevated levels of 
methylglyoxal, glyoxal and AGE residues found in plasma as well as in other tissues. In 
the initial phase ofTlDM, the effect ofthese processes would be of minimal impact and 
the primary factors determining methylglyoxal and glyoxal levels would be the 
availability of substrate, primarily glucose, and individual differences in metabolism 
affecting methylglyoxal and glyoxal formation and catabolism by the glyoxylase system. 
Hence, correlation withAl C is expected since glycemia is a primary determinant of flux 
through pathways forming methylglyoxal and glyoxal. A contributory role for 
methylglyoxal and glyoxal in complications may be evident ifthere is a relationship 
between these compounds and the activity of a ubiquitous membrane enzyme like 
Na+/K+ATPase, which seems to be affected early in DM. The most profound effects of 
methylglyoxal in inducing complications may be at the intracellular level. AGE residues 
formed intracellularly will be released into the blood in the form of free AGE residues 
and finally filtered by the kidney. MG-H appears to be important since it is produced in 
relatively large amounts on both intracellular and extracellular protein. Demonstrating 
elevated levels ofmethylglyoxal and glyoxal and free AGE residues in blood ofyoung 
TlDM patients may not only provide evidence for a role ofthese in the pathogenesis of 
DM complications, but offer potential clinical tests to identify TlDM patients at greatest 
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risk of complications by a diminished ability to respond to methylglyoxal and glyoxal 
production. This susceptibility to AGE formation would be manifested by increased 
blood levels ofmethylglyoxal and glyoxal and increased blood levels of free AGE 
residues like MG-H. These may, serve as predictors of future complications in T1DM 
independent of A1C. 
Previous studies have shown increased concentrations of plasma methylglyoxal 
(Beisswenger et al., 2003; Nemet et al., 2005), glyoxal (Lapolla et al., 2003) and certain 
plasma protein bound AGEs and free AGE residues (Kilhovd et al., 2003; Fosmark et al., 
2006) in T2DM patients or in adults with T1DM. The plasma free AGE residue that is 
present in largest amounts is the methylglyoxal-arginine adduct, MG-H1 (Ahmed 
2005D). Although studies showing increased concentrations of the dicarbonyls and free 
and protein bound AGEs in adults with DM may indicate an association with DM 
complications, they do not necessarily indicate a direct role of the dicarbonyls and AGEs 
in causing complications. Elevations in dicarbonyls and AGE formation prior to clinical 
presentation with complications provide much better evidence for a causal role. There are 
no reports so far describing the concentrations of plasma methylglyoxal, glyoxal and 
AGEs in young patients ofT1DM without complications. 
Methylglyoxal and glyoxal may affect the activity of various enzymes (Morgan et 
al., 2002; Park et al., 2003; Lee et al., 2005; and Jia et al., 2006) by promoting AGE 
formation. A potential candidate for such modifications is the membrane enzyme, Na+/K+ 
ATPase (Derham et al., 2003). Alteration ofNa+/K+ ATPase activity has been implicated 
in diabetic neuropathy (Raccah et al., 1996; and Djemli-Shipkolye A, et al., 2001) and 
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may play a role in other diabetic complications (Mimura et al., 1994; Tsimaratos et al., 
2001; and Koc et al., 2003). To date there has been no investigations into the potential 
relationship between plasma glyoxal, methylglyoxal, or plasma free AGE levels and the 
activity ofNa+, K+ ATPase. 
In this research, I focused on the following: 
1) Development of methods for measurement of methylglyoxal and glyoxal, 
and free AGE residues in human plasma. The study of methylglyoxal, glyoxal and 
methylglyoxal-derived AGEs presents many challenges. Owing to the high reactivity of 
methylglyoxal, effective capturing of the free methylglyoxal molecule for measurement 
is difficult. The methylglyoxal-derived AGEs, like MG-H, have only recently been 
described and as yet there are no robust or convenient methods for measurement of these. 
Moreover, the unavailability of pure samples of AGE residues amplifies the difficulties in 
designing and validating procedures to accurately quantify these. While the formation of 
methylglyoxal and methylglyoxal-derived AGEs may be a mechanism by which diabetic 
complications occur, the literature is relatively void of information on the levels of these 
found in young patients with TlDM before complications occur. This work will, 
therefore, involve synthesis ofMG-H standards and allow development of a method to 
provide quantitative information on MG-H in plasma. Use of an LC-MS/MS procedure 
will increase specificity of measurement. 
2) Establish the concentrations of methylglyoxal, glyoxal and methylglyoxal-
derived AGE residues in complication-free young individuals with TlDM. Do 
increased levels of methylglyoxal and methylglyoxal-derived AGE residues precede 
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complications or do they occur secondary to other alterations that result in complications? 
Providing evidence for increased levels ofmethylglyoxal and methylglyoxal-derived 
AGE residues in complication-free young patients with TlDM may provide evidence to 
support the former. Demonstrating this may also help identify TlDM individuals at 
greatest risk of early complications independent of Al C values. 
3) Determine the relationship of Al C, methylglyoxal, glyoxal and free 
methylglyoxal AGE residues with function ofNa+/K+-ATPase activity. Information 
on the levels ofRBC membrane Na+/K+ ATPase activity in TlDM without complications 
is scant. Moreover, the relationship between the levels of this enzyme and methylglyoxal, 
glyoxal, and methylglyoxal-AGEs is largely unknown. Levels ofRBC membrane 
Na+ /K+ -ATPase activity in complication-free young patients with TlDM will be 
examined and compared with levels of glycemic control, and plasma methylglyoxal, 
glyoxal, and MG-H levels. 
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CHAPTER2 
MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Study Subjects 
Blood samples from study subjects were analyzed as part ofthis parallel case-
control study. In order to examine the relationship between the levels of plasma 
methylglyoxal, glyoxal and specific free AGE residues in TlDM, four cohorts of up to 20 
subjects aged 6 to 22 years with or without TlDM were recruited. Study subjects were 
recruited from patients presenting to the Diabetes Clinic at the Janeway Child Health 
Centre Health Care Corporation, St. John's, NL for routine check-up and AlC 
measurement. Nursing staff in the clinic approached patients for participation in the study 
and written informed consent was obtained (see Appendix 1). Ethics approval for the 
study was granted by the Human Investigation Committee of Memorial University, St. 
John's, Newfoundland and Labrador. 
The four cohorts were constructed consisting of: 
1. Subjects with normal levels of AlC (<6%) without biochemical evidence of 
TlDM as controls (n=l8). 
2. TlDM subjects with good glycemic control for at least 1 year and average 
Al C <8% (n = 20). 
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3. T1DM subjects with moderate glycemic control for at least 1 year and average 
A1C levelS to 9% (n = 17). 
4. TlDM subjects with poor glycemic control for at least 1 year and average Al C 
level> 9% (n = 19). 
Clinical information including: duration of diabetes, type of insulin management, 
age, sex, and the presence of diabetic complications (Hypertension, Nephropathy, 
Retinopathy, and Neuropathy) was collected by a research nurse from chart review and 
documented (See chart audit form Appendix 2). Patients consenting to participate had a 
2 ml aliquot ofblood removed from their AlC sample for analysis ofthe biochemical 
parameters. 
Outpatient blood samples (n=l8) collected in EDT A-containing tubes from 
patients aged 6 to 21 years were used as controls. The samples were retrieved over a 2 to 
3 week period by review of hematology sample logs, and age and sex ofthe individual 
was recorded. These samples were also analyzed for A1C and had AlC levels less than 
6%. 
AlC measurements were carried out using standardized clinical laboratory 
methodology on a G7 AlC analyzer (Tosoh) using an ion exchange HPLC procedure. 
2.1.2 Chemicals and Reagents 
Unless otherwise specified, chemicals and reagents were of commercial origin 
and were of the highest grade available. 
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Ethylenediarninetetraacetic acid (EDT A), tris(hydroxymethyl)amino-methane 
(Tris), methylglyoxal, glyoxal, 2,3-hexanedione, 2,3-diarninonaphthalene (2,3-DAN), 
formic acid, trichloroacetic acid (TCA), L-lysine, t-butyloxycarbonyl arginine (Na-t-BOC 
arginine), t-butyloxycarbonyllysine (Afl-t-BOC lysine), solid copper carbonate (CuC03), 
2-bromopropionic acid, sodium acetate, sodium hydroxide (NaOH), nonafluoropentanoic 
acid (NFPA), trifluoroacetic acid (TFA), sodium chloride (NaCl), 
diethylenetriaminepenta acetic acid (DETPA), and heptafluoro butyric acid (HFBA), 
potassium chloride, magnesium chloride, ethyleneglycol bis (2-aminoethyl-ether) 
tetraacetic acid (EGTA), adenosine triphosphate (ATP), phosphoenolpyruvate (PEP), 
nicotinamide adenine dinucleotide (NADH), pyruvate kinase, lactate dehydrogenase, 
ouabain, adenosine 5'-triphosphatase (ATPase) and bovine serum albumin (BSA) were 
all purchased from Sigma-Aldrich Chemical Company (St. Louis, MO, USA). 
Concentrated hydrochloric acid (HCl; 36.46%) was obtained from Fisher Scientific 
Company (Nepean, Ontario, Canada). Methanol, acetonitrile (Optima grade), ethyl 
acetate, and ammonium hydroxide were obtained from Fisher Scientific Company (New 
Jersey, USA). Sodium hydrogen phosphate was purchased from EM Science (MERCK, 
Darmstadt, Germany). L-Lysine-(4,4,5,5-D4) (d4-lysine) was purchased from Cambridge 
Isotope Laboratories Inc (Andover, MA, USA). 
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2.2 Method for Preparation of Blood Samples 
Blood samples (about 2 ml) were centrifuged at 3000 rpm for 10 min. The upper 
plasma layer was removed and centrifuged at 13,000 rpm for 5 min to remove debris. The 
plasma was then aliquoted into at least two separate fresh microfuge tubes and stored at -
70°C for the measurement of methylglyoxal, glyoxal and free AGE residues. A pooled 
plasma sample from patients without DM was also processed and used for calibration 
matrix. 
To prepare red blood cell (RBC) membranes for the measurement ofNa+/K+-
ATPase activity, 200 111 of centrifuged blood cells, separated from plasma, was added to 
1.5 ml of 10 mM Tris-HCl (pH 7.6) containing 1 mM EDTA and vortexed for 20 sec as 
previously described (Vasarhelyi B, 1997). This hemolyzed the blood and the resulting 
hemolysate was centrifuged at 14,000 rpm at 4°C for 5 min to give a RBC membrane 
pellet. The pellet was then washed four times with the same solution and then re-
suspended each time with fresh solution. The final hemoglobin-free pellet was re-
suspended in 200 111 of 10 mM Tris-HCl (pH 7.4) and stored at -70°C for measurement of 
protein and Na+/K+- ATPase activity. 
2.3 Method for Measurement of Plasma Methylglyoxal and Glyoxal 
To carry out the work in this thesis, a new method to measure methylglyoxal and 
glyoxal was developed. Characteristics ofthis method are described in detail in chapter 3. 
47 
2.3.1 Preparation of Plasma Samples 
Plasma protein was precipitated by adding 500 J..ll of the plasma to 2 volumes of 
12% trichloroacetic acid (TCA) and mixing by vortex. The mixture was then centrifuged 
at 5000 rpm for 5 min. The protein free supernatant was transferred to a fresh tube for 
methylglyoxal and glyoxal measurements. 
2.3.2 Preparation of Calibration Standards 
The calibration curve for methylglyoxal and glyoxal was prepared using 
supernatant from a plasma pool that had the protein removed by precipitation using 2 
volumes of 12% TCA. The plasma used to prepare this pool was retrieved from non-DM 
patient blood samples. This was done to ensure that a common sample matrix was used 
for both samples and calibrators. To prepare calibration standards, 0 to 100 J..ll of 840 
ng/ml methylglyoxal and 420 ng/ml glyoxal were added to tubes, followed by 400 J..ll of 
supernatant from TCA precipitated normal plasma. The concentrations used on the 
standard curve were corrected for the concentrations ofmethylglyoxal and glyoxal in 
normal plasma to allow the calibration curve to intersect zero. 
2.3.3 Derivatization of Samples 
Supernatant from TCA precipitated plasma samples were derivatized using 2,3-
DAN before measurement. Briefly, 250 J..ll of 84 ng/ml 2,3-hexanedione (as internal 
standard) was added to tubes containing 400 J..ll of TCA precipitated plasma supernatant 
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from the T1DM groups, the control group, and standards, respectively. The final volume 
for each was adjusted to 1 ml using 10 mM phosphate buffer (pH 7.4) and the mixture 
was then incubated with 100 Ill of the derivatizing agent 0.1% 2,3-DAN for 24 hours at 
4°C. The long incubation time was critical for reproducible results. The 2,3-DAN 
derivative was then extracted into 4 ml of ethyl acetate by vortexing for 20 sec and 
centrifuging at 5000 rpm for 5 min to separate layers. The upper layer containing the 2,3-
DAN derivatives was removed and dried under a stream of nitrogen gas. The dried 
extract was finally reconstituted with 200 Ill of acetonitrile for high-pressure liquid 
chromatography-tandem mass spectrometric (LC-MS/MS) analysis. 
2.3.4 Measurement of Methylglyoxal and Glyoxal by HPLC-MS/MS 
All samples were analyzed on the Waters AllianceHT 2795- Micromass Quattro 
Ultima LC-MS/MS system. Five Ill of sample was injected each time. The 2,3-DAN 
derivatives ofmethylglyoxal, glyoxal, and 2,3-hexanedione, were separated in an 
isocratic solvent system of aqueous 0.1% formic acid and acetonitrile (35:65, v/v) using a 
C8 column (Symmetry®C8 3.5 !liD 2.1 x 100 mm, WAT058961, Water, Massachusetts, 
USA) at a flow rate of 0.30 ml/min at 25°C. In this system, the derivatives of 
methylglyoxal and glyoxal elute at about 1.7 min and 1.65 min, respectively, and the 
internal standard at 2.8 min. The run time was 5 min. The methylglyoxal-DAN product 
was determined by multiple reaction monitoring (MRM) of the transition 195> 168, with 
collision energy (CE) set at 20; glyoxal-DAN product was monitored using the MRM 
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transition 181>154, with CE set at 20; and hexanedione-DAN product was monitored 
using the MRM transition 237>208, with CE set at 22. The calibration curve was 
constructed from the ratio of response of the area under the methylglyoxal-DAN peak, or 
glyoxal-DAN peak, to the area under the hexanedione-DAN peak in different standard 
solutions. Plasma methylglyoxal and glyoxal were expressed as nmol/L. 
2.4 Method for Measurement of Free MG-Hl in Plasma 
Attempts were made to synthesize four methylglyoxal derived AGEs and measure 
both free and bound AGE residues in plasma and plasma protein, respectively. This 
synthesis effort was successful in preparing sub-milligram quantities of argpyrimidine, 
MG-H, MOLD and CEL. The synthesis and method used to measure MG-H are 
described below. Information on the synthesis and performance in the same assay system 
for the other three AGE residues are described in Appendix 3. 
2.4.1 Synthesis of MG-H 
As pure standards for methylglyoxal-derived AGEs like MG-H were not 
commercially available, MG-H was synthesized in small amounts using a procedure 
previously described by Ahmed et al. (2002) for MG-H3. This procedure produces a 
mixture ofMG-H isomers including MG-H1 and MG-H3. Briefly, 311 mg oft-BOC 
arginine (1 mmol) was dissolved in 60 ml of200 mM sodium acetate buffer (pH 5.4) 
followed by adding 0.21 mL ofmethylglyoxal solution (1.2 mmol). The solution was 
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filter sterilized by passing through a 0.2Jlm filter and then incubated at 37°C for 7 days. 
The product was then lyophilized and extracted with methanol three times. The methanol 
extracts were evaporated to dryness and further purified by preparative HPLC using a 
reverse phase Cl8 column as previously described (Ahmed et al. 2002). Collected 
fractions corresponding to t-BOC-MG-Hl were lyophilized, dissolved in 0.5 M HCl and 
were allowed to stand at room temperature overnight to hydrolyze t-BOC groups. The 
solution was lyophilized once more and repurified by LC-MS/MS using a Gemini Cl8 
semi-prep column (250xl0mm; 5 )liD; Phenomenex, USA) in a solvent system consisting 
of 0.1% TF A (aqueous) and methanol. Separation and identification ofMG-H was 
accomplished by monitoring the MRM transition of 229.1 > 114 with CE set at 9 e V. The 
collected fraction was then vacuum dried and the final MG-H product was stored at-
70°C. 
2.4.2 Sample Preparation for Measurement of Free MG-Hl in Plasma 
Plasma protein was precipitated by adding 300 Jll of 20% TCA to an equal 
volume of plasma and stored on ice for 15 min. The mixture was then vortex mixed and 
centrifuged at 4°C at 3000 rpm for 5 min to separate the precipitate. The supernatant was 
removed to a 5 mL microcentrifuge tube and used for measurement of free MG-Hl in 
plasma. 
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2.4.3 Measurement of Free MG-Hl in Plasma 
2.4.3.1 Preparation of stock solution and calibration standards 
Stock solution was prepared by dissolving the purified MG-Hl sample in water to 
give an estimated final concentration of 40 mg/L for MG-Hl. The standard curve was 
constructed by diluting the stock standard in plasma to final concentrations ranging from 
0 to 16.8 mg/L for MG-Hl. Calibration curve was corrected for endogenous free MG-Hl 
in plasma. 
2.4.3.2 Extraction of samples for the measurement on HPLC 
The supernatant ofTCA precipitated plasma samples were prepared for analysis 
by first extracting on solid phase extraction (SPE) columns. Briefly, 20 j..tl of lmg/ml c4-
lysine was added as an internal standard to 380 j..tl of the supernatant from all samples and 
prepared calibration standards. Samples were then diluted by adding 2 ml of water. The 
pH of samples was checked before loading to ensure approprate acidity for SPE. The SPE 
columns (Oasis MCX lee 30 mg, Waters) were prepared by adding 1 ml of methanol and 
vacuum drying for 10 min. This was followed by adding 1 ml ofwater to each SPE 
column to prepare the sorbent for extraction. Samples were loaded on to the columns, 
followed by washing with 1 ml of O.lN HCl and 1 ml of methanol. The retained 
components from the loaded samples were eluted with 2 ml of 5% ammonium hydroxide 
in methanol and collected in fresh tubes. The elute were dried down under a nitrogen gas 
stream and resuspended in 200 !Jl of methanol/acetonitrile (25/75) for analysis. 
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2.4.3.3 Measurement of free MG-Hl in plasma by LC-MS/MS 
All extracted samples were analyzed by LC-MS/MS on the Water Alliance HT 
2795-Micromass Quattro Ultima LC-MS/MS system. Twenty J..Ll of each sample was 
injected on a Hilic Sillica column (Atlantis® Hilic Silica, 3 J..Lm, 2.1 x 50 mm, Waters 
Corporation, Massachusetts, USA). MG-H1 and d4-lysine were separated in a solvent 
system consisting of 200 mM formate buffer in methanol, water and acetonitrile at a flow 
rate of 0.5 ml/min at ambient temperature. During the 8 min chromatographic run, the 
composition of 200 mM formate buffer was held constant at 5%. The water content was 
increased from 10% to 55% during the first 2 min, returned back to 10% in the following 
2 min, and then held constant at 10% for the remainder of the run. The content of 
acetonitrile decreased from 85% to 40% during the first 2 minutes, then increased back to 
85% in the following 2 minutes, and finally held at 85% thereafter. MG-H1 and d4-lysine 
were determined by MRM. In this system, the MRM transition, CE, and retention time 
for the analytes were 229.1>114, 9 eV, and 2.58 min for MG-H1; and 151.1>88, 8 eV, 
and 2.7 min for d4-lysine, respectively. 
The calibration curve was constructed from the response ratio ofthe area under 
the peaks ofMG-H1 to the area under the d4-lysine peak in different standard 
concentrations. The concentrations used on the standard curve were corrected for the 
concentration ofMG-H1 in normal plasma to allow the calibration curve to intersect zero. 
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The concentration ofMG-H1 was determined according to the response ratio, and was 
expressed as mg ofMG-H1 per L, assuming 100% purity ofMG-H1 standard. 
2.5 Method for Measurement ofNa+OC-ATPase Activity in Red 
Blood Cell Membrane 
2.5.1 Preparation of Samples 
The red blood cell membrane samples that were stored at -70°C were resuspended 
by sonication (Virsonic, Cell disrupter, Model16-850, Gardiner, N.Y.) prior to 
measurement of protein and Na+1K+-ATPase activity. 
2.5.2 Measurement of Protein Concentration 
Protein concentration in the red blood cell membrane samples were measured 
using the Bio-Rad DC Protein Assay (Bio-Rad, Ontario, Canada), and BSA was used as a 
standard. The standard curve was prepared using 0 to 80 J,.tl of 1.5 mg/ml BSA. Standards 
or 40 J,.tl of each sample were transferred to test tubes, followed by 500 ~-tl of Working 
Reagent A (200 J,.tl of ReagentS added to 10 ml ofReagent A, an alkaline copper tartrate 
solution) and 4.0 ml ofReagent B (a dilute Polin Reagent) and incubated for 15 minutes. 
The protein concentration was measured by absorbance at 750 nm by spectrophotometer 
(Spectronic Genesys 5, Milton Roy) and calculated using the standard curve. 
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2.5.3 Measurement ofNa+/IC ATPase Activity by Spectrophotometry 
Na+/K+ ATPase activity was measured in suspended RBC membrane samples as 
previously described (Vasarhelyi et al., 1997) but with some modification. Briefly, 760 J •.tl 
ofreagent 1 (100mM NaCl, 20 mM KCl, 2.5 mM MgClz, 0.5 mM EGTA, 50 mM Tris-
HCl pH 7.4, 1 mM ATP, 1mM phosphoenolpyruvate, 0.16 mM NADH, 5 kU/L pyruvate 
kinase, 12 kU/L lactate dehydrogenase) was incubated at 37°C for 5 min prior to adding a 
40 IJ.L aliquot of suspended RBC membranes. Decrease in absorbance was monitored at 
340 nm by spectrophotometry (Spectronic Genesys 5, Milton Roy) over a 10 minute 
period. From the change in absorbance during this time period, rate 1(total ATPase 
activity) was obtained. A 50 111 aliquot of reagent 2 (10 mM Ouabain) was then added to 
inhibit the ouabain-sensitive ATPase activity. The change in absorbance after adding 
ouabain was monitored for the next 10 minutes, and rate 2 (ouabain-resistant ATPase 
activity) was obtained. Ouabain-sensitive Na+/K+ ATPase activity was calculated as the 
difference between the two slopes and adjusted for protein concentration. The final 
activity was recorded as nmol NADH oxidizedlmin/mg protein. 
2.6 Statistical Analysis 
Data were analyzed using SPSS for Windows (release 14.0). Results are 
expressed as mean ± standard deviation. Independent sample t-test was used to compare 
groups. When several different groups were compared, ANOV A was performed with 
correction for multiple comparisons by Bonferroni method. The relationship between 
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methylglyoxal, glyoxal, MG-Hl, HbAlC, Na+1K+-ATPase activity, age, and duration of 
diabetes was analyzed using correlation analysis. Multiple linear regression analysis was 
also performed on HbAlC, methylglyoxal, glyoxal and MG-Hl to assess the ability of 
these variables to predict Na+/K+-ATPase activity. A p-value ofless than 0.05 was 
considered statistically significant. 
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CHAPTER3 
DEVELOPMENT OF METHODS FOR MEASUREMENT 
OF METHYLGLYOXAL, GLYOXAL 
AND AGES IN PLASMA 
3.1 Introduction 
Although a few methods have been established to measure methylglyoxal, glyoxal 
and certain specific AGEs, we sought to develop more specific, and time- and cost-
effective methods. This work presents many challenges: 1) pure standards for many 
methylglyoxal-derived AGEs are not available and must be synthesized; 2) a major 
problem with measuring alpha ketoaldehydes is their low concentration and high 
reactivity towards other endogenous compounds (Thomalley, 1996); 3) the spontaneous 
formation of methylglyoxal from triose phosphates during the preparation procedures can 
be a problem (Mclellan et al1992), which may be resolved by working under acidic 
conditions; 4) low concentrations of some methylglyoxal-derived AGEs also presents a 
challenge, and the sensitivity of some to degradation by strong acid (Ahmed et al., 2002) 
prevents good recovery following protein acid hydrolysis procedures. 
3.2 Development of Methods for Measurement of Methylglyoxal and 
Glyoxal in Plasma 
3.2.1 LC-MS/MS Method for Measurement of Methylglyoxal and Glyoxal 
57 
To capture and stabilize methylglyoxal and glyoxal for measurement in plasma, 
we used 2, 3-DAN as a derivatizing agent and used 2,3-hexanedione as an internal 
standard for quantification purposes. Protein was removed by using TCA precipitation 
and the protein free supernatant was used for derivatization by 2,3-DAN. Optimum 
derivatization ofthe two alpha ketoaldehydes required an incubation time of at least 24 
hours at 4 °C and calibrating standards were also prepared in the same sample matrix by 
diluting solution of pure methylglyoxal or glyoxal standards into TCA precipitated 
plasma supernatants. Figure 3.1 shows the products of derivatization ofmethylglyoxal, 
glyoxal and 2,3-hexanedione with 2,3-DAN. Formation of these products greatly 
increases the size and reduces the reactivity permitting more convenient measurement by 
chromatographic techniques. 
A LC-MS/MS based method was developed for accurate quantification of 
methylglyoxal and glyoxal. Optimum conditions for the collision induced dissociation 
(CID) products of these were determined by continuous infusion of prepared samples 
( ~ 1-10 J..Lg/mL methanol) into a Waters Micromass Quattro Ultima tandem mass 
spectrometer and using positive ion electrospray as an ion source. Optimal tuning 
conditions for the parent ion were first determined using theM+ 1 ions: 195, 181, and 237 
for methylglyoxal-DAN, glyoxal-DAN, and 2,3 hexanedione-DAN, respectively. 
Daughter ions were produced by CID by increasing the CE of argon gas until optimal 
amounts of selected daughter ions were produced. Figure 3.2 shows aCID profile for the 
methylglyoxal-DAN product. Optimum levels of the product ion of mass 168 were 
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produced when the methylglyoxal-DAN product is bombarded with argon gas at aCE of 
20 eV. The transition of 195>168 also gave sufficient specificity for selective detection of 
the methylglyoxal-DAN product and this was subsequently used in all experiments for 
specific measurement of the methylglyoxal-DAN product. Glyoxal-DAN and 2,3-
hexanedione-DAN were likewise optimally measured at the CE equal to 20 eV and 22 
eV, and using the transitions 181>154 and 237>208, respectively, to ensure selectivity 
for these products (Figure 3.3 & 3.4). 
For convenient measurement of methylglyoxal and glyoxal from biological 
samples a liquid chromatographic separation method was developed and coupled with 
MS/MS detection. Reversed phase chromatography performed on a C8 column 
(Symmetry® C8 3.5 Jlm 2.1 x 100 mm, WAT058961) using a simple isocratic solvent 
system consisting ofO.l% formic acid in water and acetonitrile (35:65, v/v) was finally 
adopted to accomplish separation. Figure 3.5 shows a typical chromatogram achieved for 
2,3-DAN derivatization products ofmethylglyoxal, glyoxal, and 2,3-hexanedione in a 
serum sample by this LC-MS/MS method. Apart from the peaks of interest there was no 
evidence of potentially interfering substances at the region of the chromatogram where 
the analytes eluted. As all blood plasma has detectable levels of methylglyoxal and 
glyoxal it was necessary to correct calibration curves for this endogenous methylglyoxal 
and glyoxal. Figure 3.6 and Figure 3.7 shows typical calibration curves for methylglyoxal 
and for glyoxal, respectively. Both were linear over the range of concentration examined. 
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Figure 3.1 The products of derivitization of methylglyoxal, glyoxal and 2,3-
hexanedione with 2,3-diaminonapthalene (DAN). The products are 2,3-hexanedione-
DAN, methylglyoxal-DAN, and glyoxal-DAN products from top to bottom. 
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Figure 3.2 CID profile for the methylglyoxal-DAN product. Spectrum was produced 
at aCE of20 eV. Capillary voltage was set at 3.0 kV; cone voltage: 90 V; source 
temperature 100°C; and desolvation gas flow was set of 461 Llhr. Protonated molecular 
ion (M+ 1) corresponds to the peak identified as 195. Positively charged ions 168, 127, 
and 115 represent daughter ions produced from the protonated molecular ion. Size ofthe 
peaks represents relative amounts. The abbreviations are: CID is collision induced 
dissociation; DAN is diaminonaphthalene; and CE is collision energy. 
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Figure 3.3 CID profile for the glyoxal-DAN product. Spectrum was produced at a 
CE of20 eV. Capillary voltage was set at 3.0 kV; cone voltage was 90 V; source 
temperature was 100°C, and desolvation gas flow was 461Lihr. Protonated molecular ion 
(M+1) corresponds to the peak identified as 181. Positively charged ions 154 represent 
the daughter ion produced from the protonated molecular ion. Size of the peaks 
represents relative amounts. The abbreviations are: CID is collision induced dissociation; 
DAN is diaminonaphthalene; and CE is collision energy. 
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Figure 3.4 CID profile for the 2,3 hexanedione-DAN product. Spectrum was 
produced at a collision energy of22 eV. Capillary voltage was set at 3.0 kV; Cone 
voltage: 90 V; Source temperature 100°C; and desolvation gas flow was set of 461 Llhr. 
Protonated molecular ion (M+ 1) corresponds to the peak identified as 23 7. Positively 
charged ions 208, 209 and 222 represent the daughter ions produced from the protonated 
molecular ion. Size of the peaks represents relative amounts. Abbreviations are: CID is 
collision induced dissociation; DAN is diaminonaphthalene; and CE is collision energy. 
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Figure 3.5 A typical LC-MS/MS chromatograph of methylglyoxal, glyoxal, and 2,3-
hexanedione derivatized with 2,3-DAN from a normal plasma sample. Levels of 
methylglyoxal and glyoxal measured in this sample were 0.52 ng and 0.26 ng, 
respectively. The profiles are 2,3-hexanedione, methylglyoxal and glyoxal from top to 
bottom. The unit of time is minutes. The abbreviations are: LC-MS/MS is liquid 
chromatography-tandem mass spectrometry; and DAN is Diaminonaphthalene. 
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Figure 3.6 Calibration curve for methylglyoxal in serum. The response ratio was 
calculated as the area under the curve (AUC) for methylglyoxal divided by the AUC for 
the internal standard. 
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Figure 3. 7 Calibration curve for glyoxal in serum. The response ratio was calculated 
as the area under the curve (AUC) for glyoxal divided by the AUC for the internal 
standard. 
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3.2.2 Discussion 
This method represents the first developed using LC-MS/MS to measure 
methylglyoxal and glyoxal in plasma and makes use of2,3-DAN as a derivatizing agent. 
Most previously described methods used HPLC and fluorescence detection, 
spectrophotometer detection, or single ion monitoring mass spectrometry to measure 
methylglyoxal in cell culture, plasma or urine. Essentially all of these relied on formation 
of diamino aromatic products for capture and detection of the dicarbonyls. In particular a-
phenylenediamine (Chaplen et al., 1996; Randell et al., 2005; Ohmori et al. 1987), and 
1,2-diamino-4,5-dimethoxybenzene (McLellan et al., 1992, Nemet et al, 2004) was 
previously used for blood samples. In our early studies we attempted to increase the 
analytical specificity for methylglyoxal using a-phenylenediamine derivatives and LC-
MS/MS. However, because of poor sensitivity due to inadequate fragmentation of this 
product in the collision chamber these efforts were abandoned. Odani et al. (1999) used 
2,3-DAN and 3,4-hexanedione as internal standard to measure methylglyoxal, glyoxal 
and 3-deoxyglucosone using an electrospray ionization LC/MS technique with 
chromatography on a C18 column. This method had relatively long chromatographic 
times in excess of35 minutes. Because ofthe greater potential of2,3-DAN derivatives 
for MS/MS analysis we used this as a derivatizing agent. This new method is an 
improvement in that it provides greater reproductility and takes advantage of the 
increased specificity of tandem mass spectrometry with less likelihood of interference 
from products with the same mass (isobaric compounds). 
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Analyte analogues labeled by stable isotopes are the best internal standard for 
MS/MS because they have similar chromatograph and fragmentation characteristics as 
the analyte itself and thereby aid in correcting for sample specific ion suppression effects 
that can affect the accuracy of any determination (Annesley, 2003 CC). Stable isotope 
labeled analogues of methylglyoxal or glyoxal are not commercially available so instead 
2,3-hexanedione was used as an internal standard because of its dicarbonyl structure. It 
was added to the protein free supernatant after precipitation of protein and helped correct 
for variable losses of derivatization products during subsequent extraction steps. All 
products are relatively similar structurally and are expected to have similar physical 
properties and extraction efficiency. 
This new method for measurement of methylglyoxal and glyoxal has the 
following advantages: 1) Improved selectivity owing to use of tandem mass 
spectrometry; 2) Shorter analysis times using 2,3 DAN as a derivatizing agent; 3) 
Measurement of both glyoxal and methylglyoxal in a single analytical run. This method 
also has the potential to measure tissue and intracellular glyoxal and methylglyoxal 
concentration as it makes use of the rather robust process of TCA precipitation to remove 
proteins and involves liquid-liquid extraction of the final derivatized products for 
analysis. It is has not yet been determined if deoxyglucosone, the other major reactive 
dicarbonyl involved in formation of AGEs, can also be measured in the same 
chromatographic run. The ability to measure deoxyglycosone would allow measurement 
ofthe three most important dicarbonyl AGE precursors present in vivo. 
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3.3 Development of Methods for Measurement of AGEs in Plasma 
3.3.1 LC-MS/MS Method for Measurement of AGEs 
A LC-MS/MS procedure was developed with the goal of analyzing levels of 4 
different methylglyoxal derived AGE residues present in free form in plasma and 
released from protein by acid hydrolysis. These four, including MG-H (Ahmed et al., 
2002), argpyrimidine (Shipanova et al., 1997), CEL (Ahmed et al., 1997) and MOLD 
(Nagaraja et al., 1996), were first synthesized by procedures described in the literature. 
However, only MG-H1 was successfully measured in this work and its measurement is 
described below. The published procedures allowed us to prepare adequate amounts of 
MG-H1 for a semi-quantitative assessment of the levels present in plasma. The relatively 
small amounts made during this work, however, was not sufficient to allow rigorous 
assessment of the purity of the preparation. Figure 3.8 shows CID mass spectra produced 
by a daughter scan of products ofMG-Hl. The identity was confirmed in comparison 
with CID characteristics previously described (Thomalley et al., 2003) 
MG-H1 and other methylglyoxal-derived AGE residues were separated on a 
Waters High Performance Liquid Chromatography system (2795 separators module 
equipped with a temperature controller) and a Micromass Quattro Ultima PT for 
ESIIMS/MS. Various sample components were resolved on a Atlantis HILIC Silica 3 J..lm 
(2.1 x 50mm) HPLC Column in an water gradient (10% to 55%) against 10 mM Formate 
Buffer and 5% Methanol in Acetonitrile over the first 2 minutes followed with isocratic 
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conditions in the high water solvent for the next 2 minutes. Flow rate was held constant at 
0.5 ml/min and the column maintained at ambient temperature. The MS method used 
positive ion electrospray with capillary spray voltage held at 3.5 kV and cone voltage of 
35 V. The elution of AGE residues were monitored by MS/MS at ionization source 
temperature of 120 °C; Desolvation gas temperature 350 °C; and desolvation gas flow of 
550 Llhr. MS parameters for amino acids and specific AGEs in our system are indicated 
in Table 3.1. Figure 3.9 shows the chromatogram for a mixture of synthesized standards 
of the AGEs separated in this system. 
A solid phase extraction (SPE) procedure on MCX columns were used to help 
clean up biological samples prior to analyses. For measurement ofthe free non protein-
bound MG-H1 the plasma protein was first precipitated by 20% TCA and this 
supernatant was mixed with d4-lysine as an internal standard prior to SPE and 
measurement ofMG-Hl. 
3.3.1.1 Chromatographic properties of MG-Hl 
Figure 3.10 shows a typical chromatogram of free MG-H1 residues from a plasma 
sample from a healthy volunteer and the same sample but with an amount of purified 
MG-H1 added immediately prior to SPE. In the spiked sample MG-Hl appears at elution 
time of about 2.6 minutes. This is similar to the chromatogram obtained for a highly 
purified sample ofMG-Hl. Free non-protein bound MG-H1levels are detectable in the 
plasma of the volunteer. 
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Table 3.1 MS parameters for amino acids and specific AGEs. The abbreviations 
are: MS is mass spectrometry; AGEs is advanced glycation end products; MOLD is 
methylglyoxal-derived lysine dimer; CELis carboxyethyllysine; and MG-H is 
methylglyoxal-derived hydroimidazolones. 
Compound Retention Time Transitions Collision Energy 
Arginine 2.55 175>116 7.0 
Lysine 2.61 147>84 8.0 
Argpyrimidine 2.21 255.2>192.2 13.0 
MG-H1 2.60 229.1>114 9.0 
MOLD 3.48 341.3>212.2 15.0 
CEL 2.77 219>130 8.0 
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Figure 3.8 CID profile for the MG-H. Mass spectra were produced at aCE of9 eV. 
Capillary voltage was held at 3.5 kV, cone voltage was set of35 V, source temperature 
was 120°C, desolvation gas flow was set at 500 (Lihr). Protonated molecular ion (M+ 1) 
corresponds to the peak identified as 229. Positively charged ions 114, 116, 166, 184, 
211, 212 represent the daughter ions produced from the protonated molecular ion. Size of 
the peaks represents relative amounts. The abbreviations are: CID is collision induced 
dissociation; CE is collision energy; and MG-H is methylglyoxal-derived 
hydroimidazolone. 
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Figure 3.9 Chromatogram of a pure sample of AGEs. The profiles are MOLD, 
argpyrimidine, MG-H and CEL from top to bottom. The level of each AGEs measured in 
this sample was 2 ).!g. The unit for time is minutes. The abbreviations are: AGEs is 
advanced glycation end-products; MOLD is methylglyoxal-derived lysine dimer; MG-H 
is methylglyoxal-derived hydroimidazolone; and CELis carboxyethyl-lysine. 
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Figure 3.10 A typical LC-MS/MS chromatograph of free MG-Hl from a plasma 
sample from a healthy volunteer and a similar sample spiked with an amount of 
purified MG-Hl immediately prior to SPE. Arrow points to MG-Hl peak. From top to 
bottom profiles are plasma sample from a health volunteer; plasma sample spiked with 
MG-Hl; and a pure MG-Hl standard. The unit for time is minutes. The abbreviations are: 
LC-MS/MS is liquid chromatography-tandem mass spectrometry; MG-Hl is 
methylglyoxal-derived hydroimidazolone; and SPE is solid phase extraction. 
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3.3.1.2 Standard curve for MG-Hl 
Figures 3.11 show a linear calibration curve for MG-H1. Increasing amounts of 
MG-H1 were recovered with increasing amounts of the purified MG-H1 added to 
samples prior to SPE. This indicates that AGE residues were being retained by the SPE 
column and appropriately released in a concentration dependent manner. The low 
recovery of other endogenously produced AGEs was a problem and prevented 
measurement ofthese in the biological samples. 
3.3.2. Discussion for Development of Methods on AGEs 
The goal of this work was to develop a relatively simple procedure for 
measurement of several methylglyoxal-derived AGE residues by LC-MS/MS. While the 
LC-MS/MS components of the method do allow separation and measurement ofthe four 
free methylglyoxal-derived AGE residues, the sample preparation was inadequate to 
provide adequate amounts of these AGE residues to measure. The chromatographic 
method described uses a single HPLC column with a total analysis time of about 8 
minutes (See Methods Section for details) to separate and measure the four MG-derived 
AGEs. This offered the potential for a significant improvement in analytical time 
compared to a previously described method with capability of measuring all four 
(Thomalley et al., 2003) which required run times of about 50 minutes. However, only 
MG-H1 was recovered from the precipitated samples for measurement. Another HPLC 
based method for measurement ofMG-H1 has also been published (Ahmed et al. 2002) 
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but requires 6-aminoquinolyl-N-hydroxysuccinidmdyl carbonate (ACQ) derivatization 
and chromatographic run times in excess of250 minutes. This is not practical for the 
analysis oflarge numbers of samples. 
The method described here offers sufficient sensitivity to measure MG-Hl that is 
free in plasma as well as that released by hydrolysis of protein. Free MG-derived AGE 
concentrations range from 10-9 to 10-6 M in plasma. Levels ofMG-Hl have been 
previously been reported at about 50 nmol/L in plasma on healthy individuals (Ahmed et 
al., 2005), exceeding the plasma concentration of CEL, Argpyrimidine, and MOLD, the 
latter two being undetectable in free form. The free AGE plasma component most likely 
represents that released from intracellular sources following intracellular hydrolysis of 
modified proteins. These free AGE residues are effectively removed by the kidney and 
excreted into the urine. A portion of these may also come from the diet (Thomalley et al, 
2003). The majority of plasma AGEs are bound to plasma protein and can be released by 
acid or enzyme-mediated hydrolysis (Ahmed et al., 2002). Our work using acid 
hydrolysis gave unsatisfactory results when analyzed by LC-MS-MS. Acid hydrolysis 
has been reported to result in excessive loss ofhydroimidazolone AGE residues like MG-
Hl (Ahmed et al., 2002). A step-wise enzymatic hydrolysis procedure has been 
successfully used by others to prepare protein bound AGEs for LC-MS/MS analysis 
(Ahmed et al., 2002). Nevertheless, LC-MS/MS still offers the best method for 
measurement of methylglyoxal-derived AGE residues. Attempts to measure these by 
other techniques have significant limitations for providing quantitative data (Ahmed and 
Thomalley, 2007). 
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Quantitative analysis of AGEs requires availability ofmg quantities of pure 
standards. These are not commercially available but must be synthesized and purified to 
high purity to use in quantitative assay methods. Synthesis procedures have been 
published for all of the MG-derived AGEs. We were successful in the synthesis of only 
very small quantities of the various standards using instrumentation available to us. Thus, 
determination of purity and accurate and precise mass ofthe final MG-Hl product was 
not possible. We made the assumption that MG-Hl standard was 100% pure and 
expressed sample plasma concentrations as mg/L based on this assumption. 
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Figure 3.11 A linear calibration curve for free MG-Hl in serum. The 
response ratio was calculated as the area under the curve (AUC) for MG-Hl 
divided by the AUC for the internal standard. MG-Hl is the abbreviation of 
methylglyoxal-derived hydroimidazolone. 
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CHAPTER4 
STUDIES ON METHYLGL YOXAL, GLYOXAL, AGES 
AND NA+/K+-ATPASE ACTIVITY IN TlDM 
4.1 Results 
4.1.1 Study Subject Characteristics 
Fifty six young complication-free TlDM patients and 18 age matched controls 
without diabetes were recruited to study the relationships between methylglyoxal, glyoxal 
and plasma free MG-Hl levels and early risk of complications as determined by Al C 
concentrations. The relationship ofthese with Na+1K+-ATPase activity, a potential target 
ofmethylglyoxal or glyoxal damage, was also examined. Table 4.1 summarizes data 
from controls and TlDM subjects recruited. Given the young age of the control subjects 
and the normal AlC values there is very little chance that an undiagnosed TlDM or 
T2DM patient exists in this group, although sample collection was anonymous. There 
was no difference in the mean age, or in the proportion of males and females between the 
TlDM and control groups. The plasma AlC (%)was higher in the TlDM group (8.5 ± 
1.3) as compared to the control group (5.0 ± 0.3). All of the TlDM patients recruited as 
part of this study, except for one subject who had been diagnosed with TlDM 1.2 years 
prior, had their diagnosis for at least 2 years. They were all receiving insulin treatment 
and none of them had diagnosed microvascular complications. 
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Table 4.1 Characteristics of controls and TlDM subjects. Values are expressed as 
mean± standard deviation and those in brackets are the range of values within each 
category. * indicates that values are significantly different from the control group by 
student t-test (p<0.05). a indicates that values are significantly different from the control 
group by ANOV A with multiple comparison correction using the Bonferroni method. 
Normal range for hemoglobin Al C (Al C) is 4- 6%. Good glycemic control was defined 
as mean AlC <8 for one year; Moderate glycemic control as mean AlC 8 to 9; and Poor 
glycemic control as mean AlC >9. The abbreviation N/A represents not applicable. 
Control TlDM Good Moderate Poor (whole group) control control control 
Numbers 18 56 20 17 19 
Age (years) 14.6 ± 4.6 15.0 ± 4.2 13.3 ± 4.4 15.3±5.1 16.2 ± 2.8 (6-22) (6-21) (6-21) (8-21) (11-20) 
Sex lOP, 8M 28P, 28M lOP, 10M 9P, 8M 9P, 10M (female, male) 
Duration ofDM N/A 7.5 ± 4.2 6.6± 3.7 8.8 ± 4.8 7.2 ± 4.3 (years) (1.2-20) (1.2-14) (3.5-20) (2-18) 
AlC (%) 5.0 ± 0.3 8.5 ± 1.3 * 7.5±0.7a 8.5 ± 0.5 a 9.5 ± 1.4 a (4.6-5.4) (6.1-12.3) (6.1-9.1) (7.7-9.8) (6.7-12.3) 
Insulin Therapy 
(number/group) 
Conventional NIA 9 1 4 4 (2 injections/day) 
Multiple (3 N/A 13 2 3 8 injections/day) 
Multiple (4 N/A 14 3 5 6 injections/day) 
Insulin pump NIA 20 14 5 1 
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4.1.2 Levels ofMethylglyoxal, Glyoxal, Free MG-Hl and Na+/~-ATPase Activity 
in TlDM 
Levels of plasma methylglyoxal, glyoxal, plasma free MG-H1 and RBC 
membrane Na+1K.+-ATPase activity were determined in both control and T1DM patients 
(Table 4.2). The mean plasma methylglyoxal (nmol/L) and glyoxal level (nmol/L), 
respectively, were higher in the TIDM group as a whole (842 ± 238, 1052 ± 515) versus 
the controls (439 ± 90, 328 ± 208) (Figure 4.1 & 4.2). Plasma free MG-H1 (mg/L) was 
also higher in the DM group (2.7 ± 1.1) versus the control group (1.7 ± 0.9) (Figure 4.3). 
RBC membrane Na+1K.+-ATPase activity (nmol NADH oxidized/min/mg protein) was 
elevated in the DM group (4.47 ± 0.98) compared to the control group (2.16 ± 0.59). 
Figure 4.4 shows Na+/K+-ATPase activity in controls and T1DM patients 
separated according to glycemic control. Individuals in the T1DM group were separated 
into two subgroups, those with a duration of diabetes of less than or equal to 7 years, and 
those with a duration greater than 7 years (based on median value for duration of 
diabetes). There was no difference in the level ofNa+1K.+-ATPase activity between these 
two subgroups. 
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Table 4.2 Levels of plasma methylglyoxal, glyoxal, free MG-Hl according to the 
levels of glycemic control in study subjects. Good glycemic control was defined as 
A1C <8; Moderate glycemic control as A1C 8 to 9; and Poor glycemic control as A1C 
>9. Values are mean± standard deviation. *indicates significantly different from control 
group by student t test. a indicates significantly different from control group by ANOV A 
with multiple comparison correction using Bonferroni method. The abbreviations are: 
MG-H1 is methylglyoxal-derived hydroimidazolone; and NADH is reduced nicotinamide 
adenine dinucleotide. 
TlDM Good Moderate Control (whole 
control control Poor control group} 
Plasma 439 ± 90 842 ± 238 * 751 ± 236 (l 819± 153(l 944 ± 250 (l 
methylglyoxal (278-597) (431-1403) (431-1403) (653-1125) (583-1375) (nmol/L) 
Plasma glyoxal 328 ± 208 1052 ±515 * 724 ± 396 1224 ±552 (l 1241 ± 552 (l 
(nmol/L) (34-638) (379-2396) (379-1414) (707-2206) (586-2396) 
Plasma 
freeMG-H1 1.7 ± 0.9 2.7 ± 1.1 * 2.8±1.1 2.6 ± 1.2 2.5 ± 0.9 
(mg/L) (0.7-4.0) (1.4-5.9) (1.4-5.0) (1.4-5.9) (1.6-5.0) 
Na+1K+-ATPase 
activity (nmol 2.2± 0.6 4.5 ± 1.0 * 4.0 ± 0.8 (l 4.2 ± 0.7 (l 5.1±l.Oa 
(NADH oxidized (1.1-3.1) (2.4-7.6) (2.4-5.3) (2.9-5.3) (3.4-7.6) 
/min/mg protein) 
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Figure 4.1 Levels of plasma methylglyoxal in controls and TlDM subjects 
separated according to the level of glycemic control. Good glycemic control was 
defined as AlC <8; Moderate glycemic control as AlC 8 to 9; and Poor glycemic control 
as AlC >9. Results are mean± standard deviation.* indicates significantly different from 
control group by ANOV A with multiple comparison correction by Bonferroni method. 
The abbreviations are: TlDM is Type 1 diabetes mellitus; and AlC is hemoglobin AlC. 
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Figure 4.2 Levels of plasma glyoxal in controls and TlDM subjects separated 
according to the level of glycemic control. Good glycemic control was defined as 
AlC <8; Moderate glycemic control as AlC 8 to 9; and Poor glycemic control as 
AlC >9. The results are mean± standard deviation.* indicates significantly different 
from control group by ANOV A with multiple comparison correction by Bonferroni 
method. The abbreviations are: TlDM is Type 1 diabetes mellitus; and AlC is 
hemoglobin AlC. 
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Figure 4.3 Levels of plasma free MG-Hl in controls and TlDM subjects 
separated according to the level of glycemic control. Good glycemic control was 
defined as AlC <8; Moderate glycemic control as AlC 8 to 9; and Poor glycemic 
control as AlC >9. The results are mean± standard deviation. Values were not 
significantly different between groups as assessed by ANOV A with multiple 
comparison correction by Bonferroni method. The abbreviations are: MG-Hl is 
methylglyoxal-derived hydroimidazolone; TlDM is Type 1 diabetes mellitus; and 
AlC is hemoglobin AlC. 
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Figure 4.4 Erythrocyte membrane Na+/~-ATPase activity in controls and 
TlDM subjects separated according to level of glycemic control. Good glycemic 
control was defined as AlC <8; Moderate glycemic control as AlC 8 to 9; and Poor 
glycemic control as AlC >9. The results are mean± standard deviation.* indicates 
significantly different from control group by ANOV A with multiple comparison 
correction by Bonferroni method. TlDM is the abbreviation of Type 1 diabetes 
mellitus. 
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4.1.3 Relationships between Plasma Methylglyoxal, Glyoxal, MG-Hl and AlC 
in TlDM 
Pearson correlation analysis was carried out to determine ifthere was a 
relationship ofmethylglyoxal, glyoxal and MG-Hl with AlC and with each other. AlC 
correlated with both plasma methylglyoxal (r = 0.635, p<O.OOl) and plasma glyoxal (r = 
0.523, p<O.OOl) levels but not with MG-Hl. Plasma methylglyoxal and glyoxal 
correlated strongly with each other (r = 0.705, p<O.OOl). MG-Hllevels correlated weakly 
with methylglyoxal concentrations (r = 0.265, p=0.05) but not with glyoxal 
concentrations. 
4.1.4 Relationships of Plasma Methylglyoxal, Glyoxal, and AlC with Na+/K+-
ATPase Activity in RBC Membrane in TlDM. 
Correlation analysis of all subjects revealed that Na + /K+ ATPase activity was 
strongly correlated with methylglyoxal (r = 0.449, p<O.OOl), glyoxal (r = 0.554, 
p<O.OOl), and AlC (r = 0.730, p<O.OOl) (Figure 4.5) (Table 4.3). Multiple linear 
regression analysis showed that Al C was a strong predictor ofNa+ /K+ -ATPase activity 
(R2=0.582, p<O.OOl), and in the presence of this information, the information on 
methylglyoxal and glyoxal did not add significantly to the predictability ofNa+/K+-
ATPase activity. Correlation analysis within each group (TlDM and controls) revealed 
no additional or stronger relationships. 
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Table 4.3 Relationships assessed by correlation analysis. The abbreviations are: 
NADH is reduced nicotinamide adenine dinucleotide; and MG-H is Methylglyoxal-
derived hydroimidazolone. 
Variable Variable r value p value 
Hemoglobin A1C (%) Methylglyoxal (nmol/L) 0.635 0.001 
Hemoglobin A1C (%) Glyoxal (nmol/L) 0.523 0.001 
Methylglyoxal (nmol/L) Glyoxal (nmol/L) 0.705 0.001 
Na+1K+-ATPase activity (nmol 
Hemoglobin A1C (%) 0.730 0.001 NADH oxidized /min/mg protein) 
Na+/K+-ATPase activity (nmol Methylglyoxal (nmol/L) 0.449 0.001 NADH oxidized /min/mg protein) 
Na+1K+-ATPase activity (nmol Glyoxal (nmol/L) 0.554 0.001 NADH oxidized /min/mg protein) 
Free MG-H1 (mg/L) Methylglyoxal (nmol/L) 0.265 0.05 
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R Sq Linear=0.582 
Figure 4.5 Linear regression of hemoglobin AlC with Na+/K'"-ATPase activity. 
(ND: non-diabetes controls; DM: patients with Type 1 diabetes) 
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4.2 Discussion 
This work demonstrates for the first time that plasma levels of both methylglyoxal 
and glyoxal, and the free plasma methylglyoxal-arginine adduct MG-Hl are elevated in 
young patients with TlDM in the absence of diabetic complications. As these patients 
had no documented renal disease, it is likely that these elevations are not due to decreased 
excretion by kidney. There is little published data on levels of plasma methylglyoxal and 
glyoxal, or plasma free MG-Hl residues in DM. Blood methylglyoxallevels have been 
shown to be elevated in a group of individuals with insulin-dependent and non-insulin 
dependent diabetes with complications compared with controls (McLellan et al., 1994). 
When compared with normoglycemic individuals, a combined group of mainly adult 
patients (ages 15 to 82 years) with TlDM and T2DM with complications showed 
significantly elevated levels of methylglyoxal in plasma, but showed no significant 
difference when whole blood levels were used (Nemet et al., 2005). Plasma 
methylglyoxal and glyoxal were higher in older adult individuals with T2DM (Odani et 
al., 1999), and remained higher than normal controls even after an intervention which 
significantly improved glycemic control (Lapolla et al., 2003). Although all TlDM 
subjects in the present study were receiving insulin therapy, the average A 1 C level was 
still significantly higher than that of the normal control group indicating a general lack of 
glycemic control. As high glucose is one source of elevated methylglyoxal and glyoxal, 
lack of glycemic control may partially explain their elevated levels. The high correlation 
between AlC and plasma levels of these aldehydes substantiates this. The high 
90 
correlation between methylglyoxal and glyoxal also suggests that they arise from the 
same source. As methylglyoxal- and glyoxal-derived AGEs are implicated in 
complications of diabetes (Hammes et al., 1991; Misselwitz et al., 2002; Lieuw-A-Fa et 
al., 2004; and Hwang et al., 2005), this finding underscores the need for stringent 
glycemic control in patients with T1DM. 
Although levels ofmethylglyoxal and glyoxal are elevated in patients in the 
T1DM group, they have yet to develop demonstrable complications. However, the 
presence of increased glyoxal likely indicates that they are already experiencing oxidative 
stress. Likewise, other sub-clinical changes may be occurring. For instance, Elhadd et al. 
(1999) demonstrated an increase in markers of oxidative stress and endothelial 
dysfunction in young patients without clinical diabetic angiopathy. It may be that the 
magnitude of elevations in aldehydes seen in our study must be sustained for a longer 
interval in order for detrimental effects to become clinically apparent. As uncontrolled 
diabetes progresses, and tissue AGEs continue to accumulate, patients may begin to 
experience complications. We have shown, in an older group ofT1DM and T2DM 
patients, that the cysteine AGEs, CEC and CMC, derived from methylglyoxal and 
glyoxal respectively, are elevated in plasma and are associated with diabetic nephropathy 
(Mostafa et al., 2007). 
The levels ofmethylglyoxal in plasma also correlated weakly with the levels of 
free plasma MG-H1, whereas the levels of glycemia as determined by Al C did not. This 
is not surprising considering that MG-Hl is a MG-derived AGE. Increased levels of free 
MG-Hl observed in individuals with diabetes, however, is not merely the result of short 
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term changes in methylglyoxallevels but also the result of intracellular proteolysis of 
intracellular and extracellular proteins modified by methylglyoxal over longer periods of 
time depending on the half-life of the protein. In the present study, levels ofMG-Hl were 
60% higher in T1DM than in controls. Others have reported a more substantial difference 
in free MG-H1levels of7 to 10 times higher when older T1DM and T2DM individuals 
are examined (Ahmed et al., 2005) or when healthy controls are compared with renal 
failure patients on dialysis where differences are greater than 10 times (Thomalley et al., 
2003). It is possible that increasing age and duration ofDM are significant factors in 
determining the accumulation of AGEs in proteins and therefore the amount of free MG-
H1 residue produced once these are hydrolysed. The impact of renal impairment in some 
older individuals may be another factor (Thomalley et al., 2003). Nevertheless, higher 
free MG-H1levels in complication free young T1DM patients suggests that even at this 
very early stage in the disease process, significant amounts ofmethylglyoxal mediated 
damage is occurring. 
The activity of a ubiquitous membrane enzyme, Na + IK+ -ATPase, in RBC was also 
measured in this research. Na+1K+-ATPase regulates active transport of sodium and 
potassium across plasma membranes, and alteration in activity of this enzyme has been 
implicated in diabetic neuropathy (Raccah et al., 1996; Djemli-Shipkolye et al., 2001) 
and may be involved in other diabetic complications (Mimura et al., 1994; Tsimaratos et 
al., 2001; Koc et al., 2003). Previous studies have shown a decrease in RBC Na+/K+-
ATPase activity in TIDM patients ranging in age from late teens to 70 years of age, and 
with and without diabetic complications (Raccah et al., 1996; Baldini et al., 1989; Besch 
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et al., 1995; Finotti and Palatini, 1986; and Jannot et al., 2002). Methylglyoxal, glyoxal, 
and AGEs are known to cause inhibition of enzymes such as glyceraldehyde-3-phosphate 
dehydrogenase, nitric oxide synthase, and glutathione peroxidase and reductase (Morgan 
et al., 2002; Park et al., 2003; Lee et al., 2005; Xu et al., 2003) causing changes 
characteristic of diabetes including altered glucose metabolism, endothelial dysfunction 
and oxidative stress ( Rodriguez-Manas et al., 2003; Elhadd et al., 1999). We anticipated 
that if methylglyoxal and glyoxal levels were high in T1DM, then RBC membrane 
Na+1K+-ATPase activity would be decreased. However, we found that the activity ofthis 
enzyme was significantly higher in DM group patients versus patients in the ND group. 
Another study in a similar group of complication-free children and adolescents with 
T1DM showed no difference in Na+1K+-ATPase activity in RBC's compared to healthy 
non-diabetic controls (Deak et al., 2003). This may be due to the shorter duration of 
diabetes (3-10 years) and better glycemic control ofthese study subjects as compared to 
subjects in other reported studies. In a study of streptozotocin-induced diabetic rats, 
Tsimarato et al. (2001) showed that Na+1K+-ATPase activity in medullary thick ascending 
limb of kidney was increased in rats at 6 weeks, but decreased at 12 weeks, after 
induction of diabetes, when compared to normal control rats. Collectively these studies 
suggest that there may be a biphasic time-dependent response in Na+1K+-ATPase activity 
in diabetes. 
Diabetes is associated with oxidative stress (Jay et al., 2006), and it has been 
suggested that low levels of oxidative stress stimulate membrane ion transport, whereas 
with sustained and increasing levels of oxidative stress, oxidative membrane damage 
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results in inhibition of these functions (Stark, 2005). A recent study showed that AGEs 
enhanced sodium channel messenger RNA and sodium uptake in renal cortical collecting 
duct cells in a time- and dose-dependent manner (Chang et al., 2007). Additionally, 
hyperglycemia has been shown to increase intracellular sodium concentrations in normal 
human red blood cells (Barbagallo et al., 1993). These processes lead to increased levels 
of intracellular sodium that may activate membrane Na+1K.+-ATPase in a compensatory 
manner in order to maintain normal intracellular sodium levels. This may explain the 
elevated levels of membrane Na+/K+-ATPase activity demonstrated in the present study. 
The high correlation of A1C, methylglyoxal and glyoxal with Na+/K+-ATPase activity, 
and the results ofthe regression analysis indicating that A1C levels are good predictors of 
enzyme activity, point to a role for glucose, methylgyoxal and glyoxal in the membrane 
alteration. As hyperglycemia, aldehyde and AGE levels, and/or oxidative stress increase 
with time, alterations to the lipid environment or to Na+1K.+-ATPase itself may eventually 
result in inhibition of the enzyme with a decrease in activity (Djemli-Shipkoye et al., 
2001; Baldini et al., 1989). 
Although speculative, the foregoing explanation would seem reasonable, and 
substantiates the concept of a biphasic response. In order to test this concept, we divided 
data from the DM group into two subgroups based on median duration of diabetes as 
described in the methods section. There was no difference between the levels ofNa+/K.+-
ATPase activity between these two subgroups. Thus, the reason( s) for these divergent 
reports of enzyme activity remains to be elucidated. Whatever the case, the elevated 
levels of Na + IK.+ -ATPase activity demonstrated in the present study appear to indicate 
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that membrane function is altered leading to changes in sodium/potassium handling. 
Na+1K+-ATPase is present in membranes throughout the body, and alteration in the 
activity of this enzyme lends itself to widespread impact. More direct effects on Na+/K+ 
ATPase activity are also possible due to the wide variety of metabolic abnormalities 
occuring during DM. As this change is occurring prior to development of complications, 
levels ofNa + IK+ -ATPase activity may foretell future renal, vascular or neurological 
complications. 
The findings of the present study have implications for clinical management of 
diabetes. The results of this research strengthen current thinking about the need to 
structure management to maintain stringent glycemic control, starting at diagnosis of 
diabetes. In the event that glucose is difficult to control for physiologic or behavioral 
reasons, supplemental or increased dietary antioxidants may be useful in preventing 
damage caused by hyperglycemia- or AGE-induced oxidative stress. Also, an agent such 
as lipoic acid, that has been shown to decrease AGEs in animals (Vasdev et al., 2000; 
Midaoui et al., 2003), and is already in use in DM in humans for treatment of neuropathy 
(Foster, 2007), may be considered to aid in the prevention of AGE-induced 
complications. 
We acknowledge the following limitations ofthis study. Although we measured 
two of the most likely aldehydes involved in AGEs formation and diabetic complications, 
other aldehydes produced from glucose catabolism and lipid peroxidation may also be 
involved in these processes, and may offer valuable information with regards to sub-
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clinical alterations. As discussed in Chapter 3, the inability to synthesize large quantities 
ofMG-Hl did not allow us to know with certainty the purity of our standard. 
4.3 Conclusion 
In young, complication-free patients with TIDM, plasma methylglyoxal and 
glyoxal levels are elevated, and are strongly associated with elevated hemoglobin AI C, a 
measure of glycemic control. Free plasma MG-Hl residues are also higher in TIDM 
patients compared with non-DM controls and correlated with MG levels but not mean 
glycemia as determined by Al C. These findings underscore the importance of stringent 
glycemic control in TIDM as methylglyoxal- and glyoxal-derived AGEs are implicated 
in complications ofDM. These young patients with DM also show an increase in the 
activity ofthe ubiquitous membrane enzyme, Na + IK+ -ATPase, indicating early membrane 
alteration which may also presage future complications of diabetes. 
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CHAPTERS 
SUMMARY AND FUTURE DIRECTIONS 
In this research, we were successful in developing novel LC-MS/MS methods to 
measure plasma methylglyoxal and glyoxal, and plasma free MG-Hl residues which 
were used to characterize concentrations of these parameters found in young 
complication free TlDM patients compared to non-DM controls. RBC membrane 
Na+1K.+-ATPase activity was also measured in the complication-free TlDM compared 
with non-DM controls. The complication-free TlDM patients had higher levels 
methylglyoxal, glyoxal and free MG-H, as well as erythrocyte membrane Na+/K+-
ATPase activity. The higher levels ofNa+ /K+ -ATPase activity in complication-free 
TlDM may suggest altered function as a result of hyperglycemia at an early stage in 
disease. The elevations in methylglyoxal and glyoxal may at least partially be related to 
glycemia as measured by Al C. Higher levels of free MG-Hl may indicate increased 
AGE formation at this very early stage and is consistent with a causal role in the 
pathogenesis of complications. Intensive insulin therapy may significantly reduce free 
MG-Hl formation. Taken together these results are consistent with a role for 
methylglyoxal and glyoxal, and methylglyoxal induced AGE formation early on in 
TlDM and may indicate a role in the pathogenesis of complications. Establishing a 
stronger link to a causal role in DM complications will require a prospective study. Many 
ofthe TlDM subjects studied in this work will eventually develop microvascular 
complications. It is tempting to speculate that those with highest levels ofMG-Hl will be 
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at greatest risk for developing early complications. A prospective clinical study with 
measurement of AGE residues like plasma free MG-Hl in complication free TlDM 
patients and then routine follow-up with examinations for evidence of complications may 
provide the necessary data to place markers like MG-Hl into routine clinical use as 
potentially modifiable risk factors for DM complications. 
MG-Hl is one of several MG derived AGEs that may exist as a free residue or 
bound in protein. The amounts ofMG-Hl synthesized for these studies were inadequate 
to provide accurate quantitative information on actual MG-Hl concentrations free in 
plasma. With synthesis and purification of larger amounts of pure standards of AGE 
residues like MG-Hl, argpyrimidine, CEL or MOLD, or even glyoxal-derived AGE 
residues, we can begin to explore and quantify other blood-based markers of AGE 
formation and correlate these withAl C in this patient group. Successful synthesis of 
relatively large amounts of these AGE residues will be of great benefit to further study on 
AGEs in animal models as well. Future work in this area may also expand into 
measurement and evaluation of free AGE residues in urine or protein-bound AGEs in 
plasma or tissue as potential markers of AGE-induced damage and risk for DM 
complications. 
In this study, the relationship between AlC, methylglyoxal, glyoxal, free MG-Hl 
with type of insulin treatment in TlDM was also examined. Although it did not achieve 
statistical significance, preliminary analysis suggested that a relationship may exist 
between the type of insulin therapy and the level of free plasma AGEs. A study using a 
larger sample size of patients on conventional therapy is warranted to further examine 
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this relationship, as the results of this may have clinical significance in choosing the type 
of insulin therapy. 
Although two of the most likely aldehydes involved in AGEs formation and 
diabetic complications, methylglyoxal and glyoxal, were measured, other aldehydes 
produced from glucose catabolism and lipid peroxidation may also be involved and may 
offer valuable information with regards to sub-clinical alterations. The level of other 
aldehydes may be explored in future study. 
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Appendix 1 
October 2003 
Faculty of Medicine, Schools of Nursing and Pharmacy of Memorial 
University of Newfoundland; Health Care Corporation, St. John's; Newfoundland 
Cancer Treatment and Research Foundation 
Consent to Take Part in Health Research 
TITLE: New diagnostic markers for children and young people with Type 1 diabetes 
INVESTIGATOR(S): Drs. E Randell, L. Newhook, S. Vasdev, and V. Gadag 
SPONSOR: 
Your child/ward has been asked to take part in a research study. It is up to you to 
decide whether he/she can be in the study or not. Before you decide, you need to 
understand what the study is for, what risks your child/ward might take and what 
benefits he/she might receive. This consent form explains the study. 
The researchers will: 
• discuss the study with you 
• answer your questions 
• keep confidential any information which could identify you personally 
• be available during the study to deal with problems and answer questions 
If you decide for your child/ward not to take part or to leave the study this will not 
affect his/her usual health care. 
1. Introduction/Background: 
Al C is a lab test measured in patients with diabetes because it is related to the 
average blood sugar level. Al C is also related to the risk of developing diabetes 
related problems called complications. These complications include: vision 
problems, kidney problems, nerve damage, and high blood pressure. There is no test, 
including Al C, that can predict early on when and ifthese problems will occur in a 
patient with diabetes. A number of recently discovered chemicals in blood may be 
useful in identifying patients who will develop complications. If these chemicals are 
more useful than Al C they may allow doctors to better treat their patients. If patients 
can be better treated this could mean that many patients with diabetes can live longer 
without complications. 
-1- Initials: __ _ 
2. Purpose of study: 
We wish to study some newly discovered chemicals that are in blood to see how they 
are related to the risk of developing diabetes complications. 
3. Description of the study procedures and tests: 
If you agree for your child/ward to take part in this study, the researchers will 
measure some of these recently discovered chemicals in the blood sample that has 
been sent to the lab for AlC. A researcher will also record information from your 
child's/ward's chart. This information will include: age, sex, how long he/she has 
had diabetes, what type of insulin he/she is receiving, Al C results, and if he/she has 
experienced any complications related to diabetes. 
4. Length of time: 
Your participation in this study will involve the time required to read this form and 
consent to have your child participate. If you consent to have your child/ward 
participate the researchers will make arrangements with the Lab for the additional 
tests to be performed on his/her AlC sample. 
5. Possible risks and discomforts: 
There are no risks directly related to participating in this study. Your child/ward will 
give a blood sample for the AlC test. Some ofthis sample will be used to do the 
additional lab tests. No additional blood will be collected from your child/ward for 
this study. 
6. Benefits: 
It is not known whether this study will benefit your child/ward. 
7. Liability statement: 
Signing this form gives us your consent to have your child/ward be in this study. 
It tells us that you understand the information about the research study. When 
you sign this form, you do not give up your legal rights. Researchers or agencies 
involved in this research study still have their legal and professional 
responsibilities. 
8. Questions: 
-2- Initials: __ _ 
If you have any questions about taking part in this study, you can meet with the 
investigator who is in charge of the study at this institution. That person is: 
Dr. Edward Randell (777-6375) 
Or you can talk to someone who is not involved with the study at all, but can 
advise you on your rights as a participant in a research study. This person can 
be reached through: 
Office of the Human Investigation Committee (HI C) at 709-777-6974 
Email: hic@mun.ca 
-3- Initials: __ _ 
Signature Page 
Study title: New diagnostic markers for children and young people with type 1 diabetes 
Name of principal investigator: Dr. Edward Randell 
To be filled out and signed by the parent of the participant: 
Please check as appropriate: 
I have read the consent 
I have had the opportunity to ask questions/to discuss this study. 
I have received satisfactory answers to all of my questions. 
I have received enough information about the study. 
I have spoken to Dr. Newhook and she has answered my questions 
I understand that I am free to withdraw from the study 
• at any time 
• without having to give a reason 
• without affecting my future care 
Yes {} No {} 
Yes {} No {} 
Yes {} No {} 
Yes {} No {} 
Yes {} No {} 
Yes {} No {} 
I understand that it is my choice to have my child/ward be in the study and that 
he/she may not benefit . Yes { } No { } 
I agree that the study doctor or investigator may read the parts of my child's/ward's 
Hospital records which are relevant to the study. Yes { } No { } 
I agree to have my child take part in this study. Yes {} No {} 
Signature of participant Date 
Signature ofwitness Date 
To be signed by the investigator: 
I have explained this study to the best of my ability. I invited questions and gave answers. 
I believe that the participant fully understands what is involved in being in the study, any 
potential risks of the study and that he or she has freely chosen to be in the study. 
Signature of investigator Date 
-4- Initials: __ _ 
Telephone number: 
Assent of minor participant (if appropriate): 
Signature of minor participant Date 
Relationship to participant named above Age 
-5- Initials: __ _ 
Appendix2 
Examination of advanced-glycation end products (AGEs) in children 
with Type 1 diabetes 
Chart Audit Form 
Date: 
--------------------
Recruitment Date: 
---------------------
Study#: ____________________ _ 
Name: 
-----------------------------------------
MCP#: ___________________ _ 
Age: ________________________ _ 
Sex: 
---------------------------
Number of years with the diagnosis of 
diabetes: 
----------------------------
Summary of past Al C values 
Date (DIMlY) AlC (%) 
1) 
2) 
3) 
4) 
5) 
6) 
Check ifthe subject has any of the following complications: 
D Hypertension 
D Nephropathy 
D Retinopathy 
D Neuropathy 
Type of Insulin management: ____________________________________ __ 
Signature of Data Collector 
Appendix 3 
In this research, synthesis for the other three methylglyoxal-derived AGE 
residues, including argpyrimidine, MOLD and CEL, were also successfully performed. 
The procedure is described as follows: 
1. Synthesis of argpyrimidine 
Argpyrimidine was synthesized as described by Shipanova et al (1997). Briefly, 
311 mg oft-BOC Arginine (1 mmol) was dissolved in 10 ml of200 mM sodium 
phosphate buffer (pH 7.4), followed by adding 0.175 ml of 1 mmol MG solution and 4 
mg ofDETPA. The mixture was incubated at 55°C for 4 days. This was followed by 
slowly adding 0.85 ml of concentrated HCl and allowing the mixture to stand at room 
temperature for 2 hours to hydrolyze the t-BOC group. The HCl was then evaporated 
under vacuum and the solution was lyophilized and purified using a C18 reverse phase 
column as previously described (Shipanova et al., 1997). The recovered argpyrimidine 
product was further purified using LC-MS/MS by a procedure similar to that used for 
MG-Hl. The peak corresponding to argpyrimidine by MRM 255.2>192.2 moniting was 
collected and lyophilized. The final argpyrimidine product was stored at -70°C for AGEs 
measurement. 
2. Synthesis of MOLD 
I 
MOLD was prepared as previously described by Nagaraj, et al. (1996). Briefly 
500 mg of ~-t-BOC lysine and 200 mg ofMG was dissolved in 5.0 ml of0.2 M sodium 
phosphate buffer (pH 7.4), and incubated at 37 °C for 16 h. The resulting solution was 
separated by cation exchange chromatography on an AG-50W-X4 (Bio-Rad) (2.5 x 7-
cm) column equilibrated with 0.02 M sodium acetate buffer (pH 5.0) at a flow rate of20 
ml!h. The column was then washed with 250 ml of buffer and eluted in a gradient of 0 to 
1M NaCl in 100 ml followed by 100 ml ofbuffer containing 1M NaCl. Fractions (3 mL) 
were then collected to which 200 Ill of2 N HCl was added and allowed to stand 
overnight to hydrolyze t-BOC group. Fractions were then pooled and lyophilized. MOLD 
was further purified by HPLC on a Synmetry Prep C18 column in a linear gradient of 
0.1% trifluoroacetic acid (TFA) in water, to 50% acetonitrile in water containing 0.1% 
TFA; 0-100% over 35 min at a flow rate of2.0 ml/min. Fractions containing MOLD were 
further purified by HPLC on a Gemini Cl8 semi-prep column and separation and 
identification of MOLD were made by MRM of the 341.3>212.2 transition. The 
collection was then vacuum dried and the final products of MOLD was stored at -70°C. 
3. Synthesis of CEL 
Synthesis of CEL was carried out based on the method described by Teerlink et 
al. (2004) which involves protecting the a-amino group oflysine by converting to its 
copper complex. To do this, 2.2g oflysine was dissolved in 5 ml of water and heated to 
100°C. Solid CuC03 was added slowly to produce a saturated copper solution. The 
copper-lysine complex was then treated with 2.3g (1.4 ml) of2-bromopropionic acid in 
II 
2.5 ml of2 N NaOH for 3 days at room temperature under sterile conditions. The mixture 
was finally adjusted to pH 2 with HCl and copper ion was removed by treating with 
hydrogen sulfide gas. The precipitated copper sulfide was removed by filtration. The 
remaining solution was evaporated under vacuum on rotary evaporator and further 
purified by preparative HPLC using a reverse phase prep C1s column as previously 
described (Teerlink et al., 2004). CEL was then further purified on a Gemini C18 semi-
prep column (250x10mm; 5 !liD; Phenomenex, USA) with monitoring by MS/MS by 
MRM of transition 219> 130 and the peak was collected as CEL. The collection product 
was evaporated to dryness in a 2 ml plastic microfuge tube and the dried product was 
stored at -70°C for use as a standard to measure plasma AGEs. (See Figure 3.9 for 
chromatogram of these compounds) 
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